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Staphylococcus aureus bacteremia (SAB), a  leading cause of community and healthcare 
associated bacteremias is well known for complications such as  a high mortality rate, 
endocarditis, metastatic infections and recurrence. The epidemiology of SAB is different 
worldwide due to differing rate of Methicillin Resistant Staphylococcus aureus (MRSA) 
and different comorbidities in the population. While most of the reports are available 
from the Western World, there is scant information in the Asian context. Hence, we 
decided to undertake this study at the National University Hospital with the main aim to 
define the outcomes of SAB. In addition, we evaluated the effect of an Infectious Disease 
(ID) consultation in a randomized trial and performed genotyping by the Staphylococcus 
Protein A (Spa) Typing method on a subset of strains. We recruited 300 consecutive 
patients with SAB making this one of the largest cohorts of SAB patients to be studies in 
Asia. .  
The SAB and MRSA bacteremia rate was 3.42 and 1.44 per 1000 discharges or deaths. 
The epidemiology was characterized by a high percentage of MRSA (42%) and 
underlying comorbidities(88.4%). The mortality, infective endocarditis and recurrence 
rate was 29, 14.5% and 9.9% of all SAB cases respectively. On a multivariate logistic 
regression, MRSA infection, elderly age, malignancies, history of skin disease, and a 
higher APACHE score were associated with mortality; persistent bacteremia and IV drug 
use was associated with metastatic infections. In MRSA patients, metastatic seeding was 
commonly isolated bony infection and infective endocarditis. 21% of the MRSA strains 
had a vancomycin MIC of 2 or higher. The higher MIC was associated with bony 
metastatic infection and persistent bacteremia.  
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An ID consultation when evaluated in a randomized trial was associated with a better 
standard of care; however, outcomes of mortality and recurrence were comparable. The 
results are still preliminary and further evaluation of other outcome parameters is needed 
before drawing conclusions.  
Genotyping of MRSA revealed 9 Spa types, 89% of which belonged to t032 (ST22, E-
MRSA15, 21%) and t037 (ST 239-241, 68%). There was only one case of C-MRSA. Spa 
type t032 was associated with more endocarditis and pneumonia, however, mortality and 
recurrence was similar to t037.  
In conclusion, the epidemiology and outcomes at our center were similar to those 
reported from the Western World such as USA or UK.  The high proportion of infections 
due to MRSA warrants an intensification of the current infection control practices. There 
is a need for use of scoring systems such as APACHE II And Charlson score to adjust for 
underlying comorbidities.  SAB patients including MRSA cases are prone for metastatic 
infections; hence a high degree of suspicion and imaging, in particular Transesophageal 
echocardiography is warranted. Amidst concerns of rising rates of the emergent E-MRSA 
15 (t032), the outcome of bacteremia due to this clone was not different from others. Spa 
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1.1 INTRODUCTION  
Staphylococcus aureus, the causative organism of Staphylococcus aureus bacteremia 
(SAB)  are Gram-positive cocci that are arranged in clusters as seen on a gram stain. This 
bacterium is extremely hardy and can survive on dried clinical material for months. It is 
also easily transmissible from person to person. The bacterium grows on common culture 
media including nutrient agar and sheep blood agar. Its ability to grow in a high 
concentration of salt and ferment mannitol has been utilized to develop selective media 
such as Mannitol Salt Agar.  
 Staphylococcus aureus can be differentiated from other members of this genus such as 
S.epidermidis and S.saprophyticus by its appearance on blood agar plates and additional 
biochemical tests(1). The characteristic colonies of Staphylococcus aureus are round, 1-
2mm, golden yellow in colour with a zone of complete hemolysis on sheep or horse 
blood agar.  In addition, Staphylococcus aureus gives a   positive coagulase test, ferments 
mannitol, is sensitive to novobiocin and produces DNAase.   
Staphylococcus aureus is among one of the most pathogenic members in its genus. It is 
armed with a range of surface proteins, enzymes and toxins that can lead to an 
inflammatory reaction at the local site and in some instances a toxin mediated effects at a 
distant site. Infections due to Staphylococcus aureus are broadly categorized as pyogenic 
or toxin mediated disease. Among the pyogenic infections, skin infections such as 
impetigo, carbuncles, furuncles, cellullitis and blephritis are common.  At times, the 
bacteria can seed the blood and cause bacteremias and endocarditis. The other pyogenic 
infections include osteomyelitis, post surgical wound infections and pneumonias. Toxin 
  
2 
mediated diseases include food poisoning due to enterotoxins, toxic shock syndrome and 
scalded skin syndrome.  
Common antibiotics used in the treatment for Staphylococcus aureus include methicillin, 
cloxacillin, cefazolin, levofloxacin, cotrimoxazole and vancomycin. The therapy is 
largely directed by the antimicrobial susceptibility profile of the organism.  Penicillin, a 
beta-lactam antibiotic, the first to be used for Staphylococcus aureus is no longer in 
common usage as almost 90% of the strains are resistant to it. Methicillin resistance in 
Staphylococcus aureus (MRSA) was first documented in 1961 and since then there has 
been a growing concern for various reasons.  Firstly, MRSA strains are resistant to other 
classes of antibiotics, thus limiting the therapeutic options to few select agents such as 
vancomycin, daptomycin and linezolid.  Secondly, MRSA is particularly notorious in 
hospital environments, commonly seen in patients with serious underlying comorbidities 
and those undergoing invasive diagnostic or therapeutic procedures during the hospital 
stay. Outcomes in these patients are poor with a high mortality rate and increased hospital 
costs and length of stay among the survivors.  Thirdly, MRSA, although mainly a 
healthcare associated issue, seems to be increasingly recognized in the community 
causing infections among healthy young adults who have not had any contact with 
healthcare facilities previously.  Finally, many countries have witnessed a dramatic rise in 
the number of Staphylococcal infections attributable to MRSA. In some countries this 
percentage is as high as 40%(2).  Due to the nature of the problem, many healthcare 
institutes across the world have implemented active surveillance programs to curtail the 
spread. Some of the common measures include screening, isolation and eradication of 
carriage especially in high-risk patients.  
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Staphylococcus aureus bacteremia or SAB although rare, is one of the dreaded 
complications of Staphyloccoccus aureus infection. In addition to a high mortality rate 
anywhere between 20-30% of all cases. (3-7), SAB is also associated with complications 
such as endocarditis, metastatic seeding and recurrences. The epidemiology and 
outcomes of SAB vary in different countries and largely depend on the prevalence of 
MRSA and underlying risk factors. Although well recognized in the Western World (3, 
7-10), there is a paucity of data from the Asian continent. Hence, this study was 
conducted to understand the epidemiology and outcomes of Staphylococcus aureus 
bacteremia in Singapore. 
 
1.2 EPIDEMIOLOGY OF SAB 
1.2.1 Incidence 
Staphylococcus aureus is a leading cause of community and hospital acquired 
bacteremias. It is the second most important cause of Nosocomial and Community 
acquired bacteremias after Coagulase Negative Staphylococcus and Escherichia coli 
respectively(11, 12). In a retrospective review across 17 hospitals in Australia, 25% of all 
bacteremias were attributed to Staphylococcus aureus(10) .  
Most of the Staphylococcus aureus bacteremia (SAB) data are available from Europe and 
North America. Over the previous two decades, many of these countries have recorded a 
marked increase in the incidence of Staphylococcus aureus infections.   Finland noticed 
an increase from 11 per 100,000 in 1995 to 17 per 100,000 in 2001 (p value <0.001)(3) 
.In Denmark, on an average, there has been a 5.3% annual increase in Staphylococcus 
aureus bacteremia incidence rate from 1981 to 2000(4).  
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In a population-based study conducted in Calgary, Canada, the average incidence rate of 
Staphylococcus aureus bacteremia was estimated at 19.7 cases/100,000 population with 
no significant change from 2000-2006. However, during the same period the rate of 
MRSA bacteremia increased dramatically (p<0.001)(5). The National Nosocomial 
Infections Surveillance reported a rise in nosocomially acquired Staphylococcus aureus 
bacteremia in the US from 1980 to 1989 (p value <0.001)(13). Many countries have 
witnessed such a rise in specific subpopulations of SAB. 
1.2.2 Mode of acquisition 
Till late, SAB was commonly defined as “nosocomial” or “community acquired” 
according to the US Center of Disease Control and Prevention (CDC) definitions(14).  
This was based on the timing of the positive blood culture. A positive Staphylococcus 
aureus blood culture drawn in the first 48 hours of hospitalization from a patient was 
assumed to be a community acquired bacteremia while a positive blood culture after 48 
hours of hospitalization is believed to be nosocomially acquired. Many authors and 
clinicians now feel the need to define a third category, namely Healthcare associated 
infection (8, 15-17). This category includes all those SAB episodes labeled as 
“community acquired” in patients with specific healthcare risk factors. The SAB 
infection in these patients was thought to be related to their healthcare exposure rather 
than a community acquired bacteremia. The need for this category arose with increasing 
number of patients seeking healthcare outside the hospital in particular, home dialysis 
and intravenous (IV) home therapy. Currently, there is no consensus on the definition of 




• IV home therapy 
• History of MRSA colonization 
• History of surgery, hospitalization, dialysis or residence in a long term facility in 
the last one year 
It appears that almost 2/3rds of all Staphylococcus aureus bacteremias are in patients 
with previous or ongoing healthcare exposure.  In a retrospective review of SAB cases 
across 17 hospitals in Australia(10) ,  51% were nosocomial, 34% community onset and 
15%  healthcare associated. In another population based surveillance conducted in 
Calgary, Canada from 2000-2006(5),  1542 bacteremic cases were reported with 39% 
nosocomial , 25% community onset and 36% healthcare associated infections. 
The impact of various modes of acquisition on the outcome is described elsewhere.     
1.2.3 Problem of MRSA bacteremia 
The proportion of Staphylococcus aureus bacteremias caused by MRSA varies in 
different countries. It is documented to be as high as 40% in United Kingdom(2) to as 
low as 1% in the Scandinavian countries of Denmark and Sweden(4) .  Most of the 
MRSA bacteremias (70-85%) are healthcare related (8, 10).   
In recent years, there have been concerns about an increasing number of MRSA causing 
community onset infections. Genotypically, strains of MRSA causing community onset 
infections (C-MRSA) are known to be different from their hospital counterparts (H-
MRSA).  Although many infections are self-limiting, the infection can be severe at times 
and lead to bacteremias. Community MRSA bacteremia is usually seen in the younger 
patients  with no serious comorbidities unlike healthcare associated MRSA which is seen 
in older patients with significant comorbidities(18).  
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The global extent of the problem of C-MRSA is not fully known. Nevertheless, many 
countries seem to be recognizing the problem. In certain countries, 15-30% of the 
community-acquired bacteremias are caused by C-MRSA(6, 19).  A 10-year (1997-2007) 
retrospective review of SAB cases presenting at a tertiary care center in Perth, Australia 
revealed that almost 10% of all the MRSA bacteremic cases could be attributed to C-
MRSA. Similar rates (12%) have been reported from the US(8). Among the Perth cohort, 
Intravenous Drug usage (IVDU)  was the only risk factor associated with C-MRSA and 
the 7-day and 30-day mortality did not vary significantly between H-MRSA and C-
MRSA bacteremia in this cohort (18)  .  
 In Singapore, the problem of C-MRSA also seems to be increasingly recognized as well. 
At a tertiary care center, a search through the microbiology archives from 2001-2004 
yielded only 8 possible C-MRSA cases, however, between May 2004 to June 2005, there 
were a further 37 isolates. All these cases appear to be imported through construction 
workers or maids and the mean age of these patients was 35 years. Although most of the 
cases (35 of 42) were cutaneous abscesses, there was one case of C-MRSA bacteremia in 
2004 in a patient with IVDU(20). A genetic analysis of C-MRSA strains by Hsu and 
colleagues showed that majority of the community MRSA strains isolated from 2000-
2005 showed the presence of Panton Valentine Leucocidin (PVL) toxin and belonged to 
multilocus type ST30 (21).  
1.2.4 The Asian Scenario 
Most reports from Asia come from experiences at tertiary care centers. Although these 
reports cannot be extrapolated to the general population, they seem to suggest a dynamic 
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epidemiology as seen in the other parts of the world. Highlighted below are the 
experiences from two countries, Taiwan and Singapore.  
1. The Taiwan Experience:  
 MRSA accounted for 53% to 83% of all Staphylococcus aureus clinical isolates in 
12 major hospitals in 2000(22) . 
 Proportion of infections attributed to MRSA has increased dramatically over the last 
decade or two. At a university hospital, this proportion was 39% in 1991 and 75% in 
2003(23).  
 The prevalence of C-MRSA has also increased over years. A study from one of the 
centers reported  a rate of  32% per year from 2001 to 2006(24).  
 As mentioned earlier, high proportions (30%) of community acquired SAB are 
MRSA(19) . 
2. The Singapore Experience: 
 At the National University Hospital, Singapore, a total of 100 patients presented with 
MSSA bacteremia within the first 48 hours of hospitalization between March 2005 to 
February 2006. Forty eight percent of these patients had previous healthcare 
exposure(25). 
 Approximately 35% of all Staphylococcus aureus isolates are methicillin resistant 
(MRSA)(26). 
 There are suggestions of an increasing number of C-MRSA isolates in hospitals. The 




1.3 RISK FACTORS  
SAB is frequently seen in the following group of patients(27)  
• Elderly patients 
• Patients with underlying comorbidities including Diabetes mellitus, 
Cardiovascular disease (CVS), Human Immunodeficiency virus(HIV), 
Carcinoma, Rheumatoid arthritis and rare blood disorders such as Job’s 
syndrome, Chediak-Hegashi syndrome etc.  
• Hemodialysis, peritoneal dialysis, and other hospital related invasive procedures  
• Presence of a foreign body in particular, orthopedic devices, prosthetic heart 
valves and urinary catheters.  
• Intravenous drug abusers 
• Surgical site infection 
• Patients residing in long term care facilities (including nursing homes) 
The risk factors for SAB vary depending on the mode of acquisition. Patients with 
community-acquired infections tend to be younger and less likely to have comorbidities 
than nosocomial or healthcare associated infection.  Community acquired SAB is 
commonly seen in IVDU’s and the underlying source of infection is not usually clear(27). 
Patients with nosocomial SAB tend to be older and frequently have the above mentioned 
comorbid conditions. Intravascular catheterisation, surgical wound infection or hospital-
acquired infections such as respiratory illnesses during the hospital stay, make these 
patients more prone to SAB.  
Healthcare associated infections are encountered in patients receiving dialysis, home IV 
therapy or in residents of long term care facilities.  The risk factors are similar to 
  
9 
nosocomial infections. The patients are older and usually have an identifiable focus like 
IV catheters or in the case of nursing home residents decubitus or foot ulcers.  
MRSA bacteremia is more commonly seen in a healthcare set up, hence risk factors 
include a longer hospital stay(28), central venous  line (CVC)(28, 29) ,surgical site 
infection(28, 29), prior antibiotic exposure(29, 30) and nosocomial  bloodstream 
infection(30-32).  
Some of the key   risk factors of SAB are further elaborated below 
Hemodialysis and SAB:  The increasing use of intravascular catheters has been cited as 
one of the reasons of an increasing prevalence of hospital acquired SAB(27). 
Staphylococcus aureus is a common infectious complication in patients undergoing 
hemodialysis. In a prospective observational study conducted over 2 years at six teaching 
hospitals in USA, 127 consecutive episodes of bacteremia were evaluated in 118 patients 
undergoing hemodialysis. Staphylococcus aureus was found to be the commonest cause 
accounting for 31% of all bacteremias in this population.(33). In addition, Staphylococcus 
aureus was more likely to cause access site infection than other microbes (p=0.0001)  
The overall incidence of SAB in hemodialysis patients has been estimated at around 0.5-1 
episodes per 100 patient hemodialysis months (34-39). The attributable mortality in these 
patients range anywhere from 5% to 19 %. Complications such as infective endocarditis 
(IE) were thought to occur at a lower frequency in these patients. However a recent study 
reported a 14% prevalence of IE among SAB hemodialysed patients. The authors used 
the sensitive Transesophageal echocardiography (TEE) method for detecting infective 
endocarditis(34)  
Hemodialysed patients are particularly prone to SAB episodes due to 
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• Breaks in the skin as occurs during intravenous catheterisation 
• Colonization of skin , the vascular access site and the hub with the 
organism 
• Impairment of the immune system due to uremia, malnutrition, iron 
overload and Diabetes mellitus.  
The risk of SAB also increases with specific hemodialysis procedures. Central lines, 
permanent catheters and Polytetrafluoroethylene grafts (PFTE) are more commonly 
associated with bacteremias in comparison to arteriovenous (AV) fistulas (40-43) 
Intravenous drug abuse:  Staphylococcus aureus is the most common bacteria causing 
infectious complications such as skin/soft tissue infection, bacteremias or endocarditis in 
IVDU(44, 45) . In a study conducted at Detroit, Michigan, SAB accounted for 57% of all 
bacteremic episodes among IVDU. Of these 42% were caused by MRSA alone, making it 
the second most common bacterial etiology after MSSA(45)  
Some of the risk factors which increase the chance of Staphylococcus aureus infection in 
IVDU are nasal colonization, use of contaminated needles, close personal contact such as 
the shooting galleries and subcutaneous or intramuscular injections(46).  
The rate of infective endocarditis is higher in IVDU patients with SAB as compared to 
non IVDU patients with SAB(47) . Moreover, IVDU’s suffering from infective 
endocarditis are also prone to thromboembolic events especially to the lung.  In spite of 
the increased occurrence of endocarditis in IVDU, the prognosis of these patients is 
favorable, perhaps due to their younger age, lack of comorbidities and right-sided 
involvement.   
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Nasal colonization: Various studies suggest that patients who are colonized with 
Staphylococcus aureus are more prone to bacteremic episodes (48, 49).  In a prospective 
study conducted in Netherlands from 1999-2001, 14008 non-surgical non-bacteremic 
patients were screened for Staphylococcus aureus. Of these patients, 24% of the patients 
carried Staphylococcus aureus. Nosocomial SAB was more common in carriers (1.2%) 
than the non carriers (0.4%)(48). 
The relationship between carriage and infection has been more widely studied in regards 
to MRSA. It appears that patients with MRSA colonization are more prone to 
bacteremias than MSSA colonizers. In a prospective cohort study conducted in Spain, 
patients admitted to the Intensive care unit (ICU) over a year’s time from 1991 to 1992 
were screened for nasal carriage of Staphylococcus aureus and MRSA. These patients 
were subsequently followed up and any SAB episode was recorded. The rate of 
bacteremia among MRSA carriers, Staphylococcus aureus carriers and non carriers was 
38%, 9.5% and 1.7% respectively(49). The increased rate of bacteremia in MRSA 
carriers was associated with an increased ICU stay, surgery and invasive procedures as 
seen in this set of patients.  
  
1.4 PATHOPHYSIOLOGY AND CLINICAL MANIFESTATIONS 
Around 80% of the general population is colonized with Staphylococcus aureus at some 
point or the other in their life(1). Around 20-30% are persistent colonizers. The 
commonest site of colonization is the anterior nares. The other sites are axilla, rectum and 
perineum .The rate of colonization has been observed to be higher in specific subgroups 
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such as health care workers, patients undergoing dialysis, diabetics, IV drug abusers and 
HIV infected individuals(1) .  
From the anterior nares, the bacterium can go on to colonise the skin. However, infection 
does not follow due to the effective innate immunity in the form of the barrier of skin and 
mucous membrane. People become prone to skin/soft tissue infections (SSI) when this 
barrier is breached as a result of trauma. The bacterium can thus gain entry into the 
underlying tissue and cause an inflammatory response to be generated. What ensues is an 
abscess formation consisting of bacteria, necrotic tissue and phagocytes.  In most 
instances, the inflammation is self-limiting to the skin. Rarely does the bacterium seed 
the deeper tissue or bloodstream. For MRSA infections, the proportion of SSI is almost 
eight times higher than bacteremia(50).  As mentioned earlier, bacteremia is more 
common in patients with specific risk factors.  
In addition to skin and soft tissue infections, the other portals of entry for SAB are 
surgical site infection, osteomyelitis, septic arthritis, pneumonia or an intravascular 
device like central venous lines and IV lines. Many a times, there is no obvious source for 
SAB. Such episodes are also labeled as primary bacteremias. Various studies have 
reported rates of primary bacteremia anywhere between 15 to 50% of all SAB (4, 5, 51-
53). The clinical picture of SAB is governed by the underlying source. Specific signs and 
symptoms of bacteremia include fever with chills and rigor, drowsiness and in some 
cases, signs of septic shock such as hypotension and DIC. Specific clues for endocarditis 




1.5 COMPLICATIONS AND OUTCOME  
1.5.1 Prognosis 
Although the proportion of deaths due to SAB has decreased after the availability of 
antibiotics, it still remains high. Various population-based studies have reported a 
mortality rate between 20-30% (3-8).  Statistics from individual tertiary care centers have 
documented an in-hospital mortality rate of 20-40% (52-59) and 30-day mortality 
between 10-25% (52, 60). Very few studies determine the long-term mortality. At a 
tertiary care center at Germany (58), the 1-year mortality rate was observed as 37.6% 
among all SAB cases. Studies at different centers in the US report a 60-day mortality at 
11.5%(60)  and 90-day mortality at 57 %(61).  
In Asia, most of the available information on mortality is from tertiary care centers and 
focus on subsets such as MRSA or community infections. In Singapore, the attributable 
mortality was 11% among 100 Community MSSA bacteremic patients presenting at the 
National University Hospital during 2005-2006(25). An older age (>65) and chronic 
pulmonary disease were predictive of mortality in this subset of patients (p<0.01).  In 
another study conducted at Taiwan, 177 patients of MRSA bacteremia were evaluated for 
their outcome. The in-hospital mortality in this group of patients was 33.3% with 60% of 
the deaths taking place in the first 14 days of hospitalization(62).  In yet another study in 
Thailand, a very high attributable mortality (48%) was noted among SAB patients(63).   
This rate was much higher than observed in the resource rich countries.  
One of the strongest predictors of mortality is the age of the patient (3-5, 7, 52, 54, 62, 
64-66). In a study conducted in Finland, the increase in incidence of SAB in elderly lead 
to an increase in annual mortality rate due to SAB from 2.6 to 4.2 deaths per 100,000 
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population per year(3). Other factors predicting mortality include MRSA infection (67), a 
lung origin(4, 5, 7, 52, 62) , unknown source , septic shock(64, 65), endocarditis (4, 7), 
persistent bacteremia(62) and metastatic infection(62) ,  a greater severity of illness and 
comorbidities (4, 7, 62, 68-70), inappropriate or a delay in institution of antibiotic (65, 
71-73) and nosocomial infection(54).   The impact of some of these factors have been 
elaborated further later in this review.  
1.5.2 Endocarditis:  
Staphylococcus aureus is a leading cause of infective endocarditis (IE) globally. In a 
prospective cohort study conducted in 39 sites across 16 countries from 2000-2003, 
Staphylococcus aureus was the etiological agent in 32% of all IE making it the 
commonest cause followed by viridans Streptococci (18%)(74). In this cohort, patients 
with Staphylococcus aureus IE were more likely to have Diabetes mellitus, a presumed 
intravascular source, IVDU and healthcare associated IE, as compared to the Non 
Staphylococcus aureus IE. The rate of embolisation and persistent bacteremia was also 
higher in the SAB cohort.  
Traditionally SAB IE has been viewed as a community acquired problem, commonly 
MSSA in origin and encountered in young patients especially IVDU’s.  However, with 
the increasing use of prosthetic devices and IV home therapy, rising rates of MRSA 
infection and use of echocardiography for detection of vegetations, it appears that a 
significant proportion of infections are also acquired in the healthcare set up. This is 
particularly true in the US where almost 33-40% of all SAB IE are healthcare associated 
(60, 74). Epidemiologically, healthcare associated IE is more common in older patients 
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with MRSA infections. It is also fraught with the problem of persistent bacteremia and is 
associated with a higher mortality (60). 
Worldwide, the incidence of IE in SAB varies anywhere from 5-15 % (4, 5, 7, 60, 65, 
75). In Quebec, between 1993 to 2005, the cases attributable to endocarditis increased 
from 4% to 11%(7). The proportion of IE cases due to MRSA has been noted to be as 
high as 40% in certain regions(74).  
Endocarditis portends a high mortality rate in patients with SAB. Most studies have 
reported a mortality rate > 30% (4, 7, 60, 70). Hence it is important to identify SAB 
patients who are at risk of IE and IE patients at risk of mortality. Some of the factors 
believed to be predictive of IE in patients with SAB are persistent bacteremia(60, 76), 
presence of a prosthetic valve(60, 76) prior endocarditis(60),  IVDU(60), community 
acquisition(60) and unrecognized source(60, 76). Patients with MRSA are more prone for 
persistent bacteremia (60, 76) and both MRSA and persistent bacteremia show a strong 
trend towards mortality (60, 76).  
Echocardiography is also being increasingly used to diagnose additional cases of 
endocarditis. Currently, two modalities are used for diagnosis of SAB IE: Transthoracic 
echocardiography (TTE) and Transesophageal echocardiography (TEE). TEE is more 
sensitive than TTE in detecting vegetations. In a series of 103 patients, valvular 
vegetations were obtained in 21% of patients with TEE as compared to 7% with 
TTE(77). In addition to overall sensitivity, TEE is particularly useful in picking up 
smaller size vegetations, vegetations on prosthetic heart valves and complications such as 
abscesses. In the past, most of the nosocomial SAB episodes never had an 
echocardiographic evaluation, as many believed this to be a low risk population. 
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However, a prospective evaluation showed that almost 25% of patients with catheter 
SAB had evidence of endocarditis as suggested by TEE(77). Hence, many believe in a 
routine echocardiographic evaluation for all patients with SAB.  
 Although more sensitive, TEE is not always routinely feasible due to the invasive nature 
of the procedure. Some centers recommend a routine TTE for all patients with SAB and 
reserve TEE in patients with a negative TTE especially where the risk of endocarditis is 
high, for instance, IVDU, community acquisition with unknown source, patients with 
prosthetic heart valves, persistent fever, persistent bacteremia or where a short course of 
antibiotics is being considered. (78).  
1.5.3 Other complications and recurrence 
As many as 30% of non-infective endocarditis SAB are associated with metastatic 
complications (79-82). Secondary metastatic infection can involve bone and joints and 
viscera like the lung, spleen, liver, kidney and brain. Among bony metastatic infection, 
vertebral osteomyelitis and septic arthritis especially of the knee joint and sacroiliac 
joints are common. (78). Hence, a high index of suspicion is needed when a patient with 
SAB presents with back pain. Pulmonary metastasis is common entity among IV drug 
abusers with Tricuspid valve endocarditis.  
Bacteruria is another consequence of bacteremia. Many believe that is it the consequence 
of renal seeding of the bacteria.  Whether it is a surrogate marker of bacteremia is 
uncertain(78). Many patients with concomitant bacteremia and bacteruria have 
underlying urinary pathology and in particular, a urinary catheter which could be the 
cause of bacteremia. Nevertheless, bacteruria in a SAB patient without a catheter could 
serve as a surrogate marker of metastasis and must prompt a detailed evaluation for other 
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metastatic sites (78). Metastatic infections usually need a longer course of antibiotics and 
at times a surgical intervention. In the absence of an adequate treatment, the secondary 
foci could lead to future relapses and recurrences. 
The rate of recurrence in SAB infections appears to be anywhere between 2.5 to 12% (9, 
53, 54, 64, 83-85).  Recurrences can be due to infection with the same strain (relapse) or 
due to a different strain (reinfection). Some investigators believe that relapses occur 
earlier than reinfection. (70, 86).  Some of the risk factors associated with relapse include 
persistent bacteremia(54), failure to remove source(54), vancomycin treatment (54, 85), 
native valve disease(70) and endocarditis(70) 
 
1.6 METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS AND    
OUTCOMES 
The impact of MRSA on mortality has been studied extensively. Many studies report a 
higher mortality rate among patients with MRSA bacteremia as compared to MSSA 
bacteremia (5, 7, 56, 61, 87-90). However, it is not certain if this higher mortality is 
because of underlying comorbidities, a longer hospital stay and delay in antimicrobial 
stay in patients with MRSA bacteremia. 
In order to understand the impact of MRSA on mortality, a meta-analysis was conducted 
by Cosgrove and her colleagues(67). They   included thirty-one cohort studies from 1980 
to 2000 that had cited numbers and mortality rates for patients with MSSA and MRSA 
bacteremia. Barring four studies, the rest of the studies observed an increased mortality 
among MRSA bacteremic cases. A statistically significant difference in mortality was 
observed in only seven studies. All studies combined, MRSA bacteremia was associated 
with a higher mortality with an OR of 1.93(CI: 1.54-2.42, p value<0.001). The increased 
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mortality was observed even after adjusting for comorbidities and severity of illness. The 
authors postulate that the increased mortality observed in MRSA could be a result of a 
delay in the institution of appropriate antibiotics or due to the decreased efficacy of 
vancomycin as compared to beta lactams.      
One of the major limitations in understanding the impact of MRSA on the outcome is the 
lack of consensus on how to evaluate underlying comorbidities. Commonly studies 
employ comorbidity scores such as the Charlson comorbidity score (64), APACHE II 
(91)  or McCabe Jackson score(92) to quantify the severity of illness. In regards to 
Staphylococcus aureus bacteremia, there is a wide heterogeneity in these indices used 
across studies. Hence, the varying results.  
It appears that MRSA also has a significant impact on the length of hospital stay and on 
hospital costs (72, 93-98). The length of stay is almost 1.3-1.4 fold longer for MRSA 
patients as compared to MSSA patients(72). In the same study, MRSA bacteremic 
patients incurred a higher cost of hospitalization.  On an average, patients with MRSA 
infection had a 1.3-1.8 fold or $3800- $10,000 higher infection related costs compared to 
MSSA patients (57, 72). Greater comorbidities, slower clinical response have been cited, 
as reasons for a longer hospital stay observed with MRSA.  
The impact of MRSA on the length of stay and hospitalization costs seems to extend to 
bacteremias as well. In a matched case control study of nosocomial bacteremias, MRSA 
bacteremias had 3 fold increase in costs as compared to MSSA bacteremias(99). 
 
1.7 REDUCED SUSCEPTIBILITY TO VANCOMYCIN AND OUTCOMES 
The reduced susceptibility (Vancomycin Intermediate Staphylococcus aureus-VISA) and 
resistance to vancomycin (Vancomycin Resistant Staphylococcus aureus-VRSA) is 
  
19 
defined microbiologically based on minimum inhibitory concentration (MIC) to 
vancomycin. The Clinical and Laboratory Standards Institute (CLSI) revised MIC values 
for vancomycin susceptibility in January 2006 bringing down the cutoff for VISA from a 
MIC of 4 to an MIC of 2. This was largely based on a Working Group report which 
suggested poor outcomes in patients with an MIC of 4 (100). The CLSI breakpoints are 
given in Table 1 (101). Additionally, strains of Staphylococcus aureus are defined as 
hetero VISA (hVISA) if they are sensitive to vancomycin at a breakpoint of <=2, but 
show a higher MIC (4-8 ug/ml) when tested by other methods(101).  
Unlike resistance to most of the other antibiotics such as penicillin and methicillin, 
resistance and a reduced susceptibility to vancomycin appeared late after the introduction 
of the antibiotic in 1956. In May 1996, the first report of MRSA with a reduced 
susceptibility was reported from Japan(102). Subsequently, many countries have reported  
cases of VISA(103-111). Frank resistance or VRSA is a rare event with scant reports 
worldwide(112-114).  
The mechanism of resistance for VRSA is different from VISA. All the VRSA strains 
have shown the presence of van A gene which is commonly responsible for vancomycin 
resistance in enterococci. The van A gene is present on a plasmid and hence it is possible 
that Staphylococcus aureus might have acquired the gene through intraspecies transfer. 
Van A when present confers high level vancomycin resistance with MIC as high as 512 
in strains.  
VISA/hVISA appears to be an adaptive response of MRSA strains when subjected to 
prolonged exposure to vancomycin. In vitro data shows that phenotype of MRSA 
exposed to previous vancomycin is different from the vancomycin naïve MRSA. Isolates 
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with a prior exposure to vancomycin have higher MIC’s and a decreased vancomycin 
killing at 24 hours(115). 
 
Table 1 Breakpoints for vancomycin susceptibility/resistance* 
Label Vancomycin MIC 
breakpoint 
Vancomycin susceptible Staphylococcus aureus 
(VSSA) 
<=2 




Vancomycin resistant Staphylococcus aureus 
(VRSA) 
>=16 
HVISA (Hetero VISA) <=2 :on routine testing 




*CLSI guidelines:Central Laboratory Standards Institute/NCCLS. Performance standards 
for antimicrobial susceptibility testing. Sixteenth Information Supplement M100-S16 ed: 
Wayne PA, CLSI; 2006 
 
Unlike VRSA, no single gene can be attributed to the VISA phenotype. Although Agr 
genotype II is strongly associated with VISA, not all the VISA strains have this genotype 
and results are still preliminary in solely implicating the AGR operon and its 
malfunctioning as the cause of VISA(116). Instead the current understanding is that 
VISA seems to be a result of various genetic alterations that are inducible and thus can be 
switched on and off depending on the environment. The end result of these alterations is 
an altered cell wall physiology and structure. There is evidence of increased number of 
D-Ala D-Ala residues, which are false targets for vancomycin on the cell wall. Binding to 
these residues leads to a reduced diffusion coefficient and prevents vancomycin access to 
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the actual site of action. On the other hand, there also appears to be cell wall thickening 
due to reduced peptidoglycan crosslinking, reduced autolysis and  lower cell wall 
turnover(117).  
VISA/hVISA are becoming a concern as a result of the poor outcomes observed in 
patients with this phenotype.  Even among VSSA (Vancomycin susceptible 
Staphylococcus aureus), there is mounting evidence of a poor outcome at  higher MIC’s 
(118-121).  In a study conducted by Sakoulas and colleagues, patients with an MIC of 
<=0.5 have 56% efficacy with vancomycin in comparison to patients with vancomycin 
MIC 1-2, for which the noted efficacy was 9.5%(118). In another case control study 
involving patients undergoing hemodialysis, the outcome of patients with MRSA 
bacteremia with a vancomycin MIC >2 (n=17) was compared with a group of patients 
with MIC <=0.5 (n=33). The authors found that patients with a higher MIC had increased 
mortality (35% vs 24%) and increased hospitalization costs(119). Persistent bacteremia 
and endocarditis are also thought to be more commonly associated with 
hVISA/VISA(122-124).   
Owing to the difficulties in detection and the heterogeneity in methodology of detection, 
the exact prevalence of VISA/hVISA worldwide is not exactly known. Worldwide rates 
vary anywhere between 0-50% (19, 103, 106, 122, 123, 125, 126).   In one such study 
determining the prevalence in Asia, 1357 MRSA isolates from 12 Asian countries 
including 87 isolates from Singapore were tested for hVISA by the agar screen method 
containing 4mg/L of vancomycin(103). A positive growth was confirmed by population 
analysis which by and large is considered the best method for detection of hVISA (127).  
There were 58 (2.3%) hVISA in this cohort. The prevalence in different countries varied 
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from 0-8% and was noted be around 2.3% in Singapore.  Using yet another method, the E 
Test Macromethod, heteroVISA was found to be increasingly in prevalence, with rates as 
low as 2.2% from 1986-1993 to 8% in 2003-2007 among isolates collected from a 
healthcare center in Detroit(126). Interestingly, in this study, almost 60% of the hVISA 
isolates were from the blood. Unlike hVISA, the rate of VISA was noted to be stable in 
the study   and varied from 0.4-2.3%.  
The problem of VISA is aggravated by the limited therapeutic options. One approach to 
treatment is to increase the dosage of vancomycin; however this is fraught by serious side 
effects. There is also new mounting evidence to suggest that the response of such patients 
does not necessarily improve with increasing the vancomycin dosage (124, 128).  New 
drugs like linezolid, daptomycin, dalbavancin, oritavancin appear promising; however, 
emergences of resistance to these agents have already been documented.  
 
1.8 INFECTIOUS DISEASE (ID) CONSULTATION ON OUTCOMES  
Specialist consultation is known to improve the outcome of various illnesses (129, 130). 
However, it is not known if such an effect is seen with patients with Staphylococcus 
aureus bacteremia.  Specialist ID consultation for SAB could help patients by 
recommending appropriate antibiotics, removing the source and detecting metastasis.  
Few studies in the past have shown a beneficial effect of an ID consultation. In a study 
conducted by Fowler and colleagues(131) at the Duke Medical Center,  ID 
recommendations were provided to 244 patients with Staphylococcus aureus bacteremia. 
Patients were followed for 12 weeks after their initial episode of bacteremia. At the end 
of 12 weeks, outcome parameters of death and recurrence were compared in two groups 
namely, patients for whom recommendations were followed (n=112) versus patients for 
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whom recommendations were not adhered to or partially followed (n=132). Patients for 
whom recommendations were followed were less likely to have relapses (6.3%) versus 
patients in the other group (18.2%). This was statistically significant. However, no 
difference in the mortality rates was observed for both groups.  
In another recent study in 2005, patient’s characteristics, outcomes and standard of care 
was compared for SAB cases before (n=127) and after the start of the policy of 
mandatory ID consultation (n=98)(132). They found that the number of ID consultations 
had increased from a prior 53% to 90% of all cases. Consultations occurred early in the 
course of infection. The standard of care was found to be better in the year following 
routine consultation. Echocardiography was more common (73 vs. 53%, p=0.01), more 
intravascular catheters were removed (89 vs. 73%, p=0.05) and appropriate antibiotics 
were more commonly instituted (92 vs. 67%, p=0.001). Recurrent bacteremia and overall 
mortality was lower after the policy change (10 vs. 4, 12 vs. 6, respectively). However, 
these results were not statistically significant.  
 
1.9 ANTIBIOTIC THERAPY AND OUTCOMES 
The choice and duration of antibiotics for Staphylococcus aureus bacteremia depends on 
the presence or absence of the following factors 
• Whether the isolate is MRSA or not  
• Whether there is a removable source of infection for example a central line 
• Presence of complications like endocarditis 
• Risk for developing complications or recurrence 
• History of specific drug allergies 
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1.9.1 Drug of choice 
 The drug of choice for MSSA is penicillin (where the isolates are penicillin sensitive), 
oxacillin/nafcillin/flucloxacillin or cefazolin. The drug of choice for MRSA is 
vancomycin.  
Vancomycin is not recommended as a definitive treatment for MSSA bacteremia as there 
is mounting evidence of its inefficacy as compared to nafcillin/oxacillin.  In a prospective 
multicentre study conducted in six tertiary care hospitals in the US, nafcillin had fewer 
failure rates as compared to vancomycin for MSSA bacteremia (0 vs. 19%)(84). In 
another case control study, 27 cases of MSSA bacteremia receiving vancomycin were 
compared with 267 patients receiving nafcillin. The mortality rate of patients receiving 
vancomycin was higher as compared to the group receiving nafcillin (37% vs. 18%, OR 
3.3, CI: 1.2-9.5, p value =0.02)(133). Few studies have also shown that a poor outcome in 
terms of mortality or delayed clearance is present even if an empirical vancomycin is 
switched later to a beta lactam agent (134, 135). In light of this information, vancomycin 
is recommended as the mainstay of treatment of MSSA bacteremia only in cases of 
serious allergies(136).   
1.9.2 Dosage 
Following are the recommended dosages for treating SAB(137) 
Penicillin: 4 million units every four hours 
Nafcillin or oxacillin (Cloxacillin is used in Singapore): 2gm every 4 hours 
Cefazolin: 2gm every 8 hours 




Many clinicians prefer using such high doses so as to prevent metastatic seeding and 
recurrences. Also, there is evidence that a lower dosage may be associated with a poor 
outcome. In a evaluation of patients with SAB, Jensen et al found that a lower dosage of 
beta lactam (<4gm for cloxacillin) was associated with a higher mortality and recurrence 
rate (65) 
1.9.3 Route of administration 
 The intravenous route is the preferred route of administration for MRSA or MSSA 
bacteremia(137).  Compared to intravenous route, oral therapy has of limited 
bioavailability, poor compliance and gastrointestinal side effects, hence is not 
recommended for serious infection. Oral therapy is reserved for patients who refuse 
intravenous therapy or if the patient is keen on going home and cannot follow up in an 
outpatient set up where IV therapy can be provided.   
1.9.4 Duration of therapy  
 For a long time, patients with SAB were routinely treated with a long course of 
antibiotics, presumably because SAB was believed to have a high rate of complications. 
However, later studies suggested a shorter course of antibiotics (10-14 days) to be suffice 
for a catheter related infection (83, 138). In 1998, investigators from the Duke University 
published their treatment recommendations(131). They believed that treatment depends 
on clinical findings, surveillance blood cultures and echocardiography. They 
recommended a longer duration of antibiotics for patients with metastatic seeding of 
bacteria, a deep source of infection such as a joint/prosthetic infection or infective 
endocarditis, a positive surveillance blood culture or a surveillance echocardiography 
suggestive of vegetations. For uncomplicated SAB, they recommended a 7-14 day 
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treatment. Although many centers have adopted such a policy for determining the 
duration, it is still not an absolute rule. At a recent Clinical consensus conference, 45% of 
the respondents (79/206) felt that uncomplicated SAB defined as catheter infections, with 
negative follow up blood cultures, negative TEE, absence of prosthetic device and lack of 
clinical evidence of metastatic infection could be treated with 7-14 days of antibiotics. 
Although many participants agreed on a 14 day treatment, they believed that such 
patients should be followed up regularly in order to prevent relapses(139). The duration 
of therapy is thus finally based on clinical judgment.  
1.9.5 Optimal antibiotics and outcomes 
The results of most studies which aim at looking at the role of optimal/non optimal 
antibiotic therapy on outcome measures such as recurrence or mortality are confusing 
mainly because of the lack of consensus on definitions for optimal antibiotics for SAB, 
differing mortality definitions used and the presence of serious underlying comorbidities . 
In general, MRSA bacteremic patients have a delay in treatment as compared to MSSA 
bacteremic patients (61, 71, and 88). However, only few studies find an association of 
this delay in treatment with mortality(71) , while others don’t(61, 88, 140). Similarly, 
some studies show that optimal antibiotic is associated with lower mortality (9, 73, 141, 
142), especially so with MRSA bacteremia, while other studies fail to find such a 
difference (31, 62, 89).   
The effect of antibiotics on recurrence is even more unclear. Logically, it would seem 
that patients receiving a longer course of antibiotics would be less likely to relapse. 
However, two previous studies have failed to show such an association (54, 84). In one 
study, treatment for less than 14 days did not increase the relapse rate in patients having 
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short bacteremias (less than 3 days). Infact, in this study a 4-6 week antibiotic proved 
inadequate in many patients with delayed clearance of bacteremia receiving vancomycin 
therapy.  In both studies factors such as failure to remove the source or endocarditis were 
associated with recurrences.  
These findings do highlight the complexity of SAB, which cannot be tackled by antibiotic 
treatment alone. Indeed, management needs to addressed in a multipronged approach 
consisting of removal of the source of infection as early as possible, active search for 
metastasis and adequate management of such infections such as valve replacement for 
serious vegetations and effective control of underlying comorbidities. In view of such an 
approach, there would perhaps be a need for a combined care provided by the primary 
physician, Infectious disease physician and surgeons where needed.  
 
1.10 REMOVAL OF SOURCE AND OUTCOMES 
The role of the removal of source is highlighted by the fact that most line related 
infection couldn’t be cured by antibiotic treatment alone. The presence of a catheter 
increases the chance of recurrence in such patients (85, 86).  Indeed, in one study, 
catheter salvage was associated with a treatment failure in 68% of patients(143). In 
another retrospective study involving 238 patients, an eradicable source was associated 
with a lower mortality as compared to a noneradicable source. In this cohort, the 
mortality of MRSA and MSSA (11 vs. 13%) was similar in patients with eradicable focus 
of infection(144). Although the removal of the source is important to prevent recurrences, 
studies show that this might not prevent the development of complications (143, 145).  
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1.11 GENETIC ANALYSIS OF STAPHYLOCOCCUS AUREUS 
BACTEREMIA   
1.11.1 Background 
Typing methods are commonly used to define the epidemiology, determine clonality and 
assist in outbreak analysis of any infectious disease. A wide range of such methods is 
available for Staphylococcus aureus with genotypic methods gradually replacing the 
conventional phenotypic methods. Although we have a wide range of technological 
platforms to work with, no single method has all the ideal characteristics needed of a 
typing method. Hence the use of any method depends on the aim of typing, the properties 
of the method and logistics in terms of the cost and the technical expertise required.   
In regards to MRSA typing, Pulse Field Gel Electrophoresis (PFGE) and Multilocus 
sequence typing/SCC Mec typing  (MLST) are considered the reference methods against 
which newer genotypic methods are evaluated(146, 147). PFGE consists of whole 
chromosome analysis following restriction enzyme digestion with rare cutters such as 
Sma I. The resulting fragments are separated and analysed using a special form of 
electrophoresis. PFGE has a high discriminatory power and is currently considered the 
gold standard for many bacterial typing(148). Many prefer using it for an outbreak 
analysis as it has a good resolution for genetic microvariations(147). However, it is 
cumbersome, time consuming and does not allow interlaboratory comparison.  
MLST is the analysis of mutations on the sequences of seven housekeeping genes of 
Staphylococcus aureus. MLST is increasingly becoming popular as this analysis enables 
intercountry and intercontinent comparison.  Worldwide, an online website maintains the 
databases of all the MLST types, also called ST types (www.mlst.net).  Although MLST 
has a lower discriminatory power than PFGE, the concordance rate between the two 
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methods is good. An international nomenclature using MLST typing in combination with 
SCC Mec typing has been widely used to establish the circulating clones worldwide. 
(149) SCC mec is a mobile genetic element found in all strains of MRSA. Currently 
seven types I-VII have been described in different strains and this is determined by 
molecular methods (146).    
In the last decade, Spa Typing has also found wide acceptance because of its ease of 
performance, faster results and good interlaboratory comparison.  Spa typing is the 
sequence analysis of the Spa gene, which codes for Protein A, a well-known surface 
protein of Staphylococcus aureus. . Strain differences in Spa gene is the result of a 
polymorphic X region which consists of a 24 base pair repeat unit, the number and the 
position of which varies in different strains of MRSA, largely due to deletion, duplication 
or point mutation. (150). Spa typing has a discriminatory power between that of PFGE 
and MLST. Hence, many believe that this typing can discern both micro and 
macrovariation and be used for both sudden outbreak analysis  and establishing clonality.  
Spa typing, PFGE and MLST showed 100% typebilility in various studies and a good 
concordance was obtained for all three methods (147, 151-154).  The discriminatory 
power (defined as the probability that a typing system will assign the same strain type to 
strains randomly selected from the same group) of Spa typing and PFGE was above 90% 
in most studies (147, 151, 153, 154) 
1.11.2 Genotyping of MRSA and Staphylococcus aureus bacteremia 
Genotyping of large worldwide collections of MRSA have revealed that MRSA strains 
are highly clonal(146).  Table 2 shows the various clones circulating worldwide and their  
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Spa and MLST/SCC mec types.  In a PFGE analysis of 864 isolates, 82% of which were 
from blood, two clones namely, USA 100 and USA 300 contributed to 87% of all MRSA 
invasive episodes (8). Many other countries have also been able to attribute majority of 
their MRSA isolates to one or two circulating clones (18, 22, 155-157). Interestingly, 
many countries have also witnessed a shift in the circulating clones of MRSA in the last 
decade or so. In the US, unlike a decade age, almost 38-49% of all healthcare infections 
seem to be due to community MRSA clone USA 300(8, 155, 158). This clone, typically  
sensitive to antibiotics including clindamycin and ciprofloxacin has been gradually 
replacing USA 100, a multidrug resistant MRSA clone. In Singapore, MRSA sensitive to 
cotrimoxazole and gentamicin was first documented in 1997 but increased dramatically 
in numbers in 2003. This clone of MRSA was identified by MLST as the E-MRSA 15 
clone, a genotype commonly found in European countries (ST22-IV)(156). In 2004, E-
MRSA 15 constituted 18% of all MRSA isolates. Similar shifts in epidemiology has also 












Table 2 Overview of the major clones of healthcare acquired methicillin-resistant 
Staphylococcus aureus (MRSA) 
 (Adapted from: Deurenberg R, Vink C, Kalenic S, Friedrich A, Bruggeman C, Stobberingh E. The 




type SCCmec type Spa Type 
Archaic 250 I t008, t009, t194 
Southern Germany 228 I t001, t023, t041, t188, t201 
UK EMRSA-3 5 I t001, t002, t003, t010, t045, t053 
, t062, t105, t178, t179, t187, t214, 
t311, t319, t389, t443 
Iberian 247 I t008, t051, t052, t054, t200 
Irish-1 8 II t008, t024, t064, t190, t206, t211 
New York/Japan 5 II t001, t002, t003, t010, t045, t053 
 t062, t105,  t178, t179 ,t187,  
 t214, t311, t319, t389, t443 
UK EMRSA-16 36 II T018, t253, t418, t419 
Brazilian/Hungarian 239 III T030, t037, t234, t387, t388 
Berlin 45 IV t004, t015, t026, t031, t038, t050 
t065, t204, t230, t390 
Paediatric 5 IV t001, t002, t003, t010, t045, t053, 
t062, t105, t178, t179, t187 
t214 t311, t319, t389, , t443 
UK EMRSA-2/-6 8 IV t008, t024, t064, t190, t206, t211 
 
UK EMRSA-15 22 IV t005, t022, t032, t223,  







Various studies have also have tried to ascertain if specific genotypes are associated with 
invasive infections including bacteremias. Results are conflicting. A study conducted on 
an oxforshire collection of MRSA isolates did not find any such association (159). 
However, in a recent study conducted at the Duke Medical Center MLST clonal 
complexes CC5 and CC30 and spa types 2 and 16 were more represented in the 
bacteremic group(160).  Another group of investigators have reported a higher prevalence 
of enterotoxins in patients with an invasive disease (160-162).  With the increasing use of 
typing methods especially technologies such as microarrays which are able to look at the 
expression of large number of genes, more associations can be studied and are likely to 
















1.12 AIMS OF THE STUDY 
This study was conducted with the main aim to define the epidemiology and outcomes of 
Staphylococcus aureus bacteremia.  Following were the specific aims of the study 
1. To define the epidemiology of   Staphylococus aureus  bacteremia  
2. To define the rates and predictors of adverse outcomes such as mortality, 
metastatic infections and a high vancomycin MIC 
3. To ascertain if an Infectious Disease consultation (ID) is associated with a better 
outcome in patients with Staphylococcus aureus bacteremia 
4. To ascertain the molecular types of MRSA and MSSA using the Staphylococcal 






























2.1 EPIDEMIOLOGICAL METHODS 
Data was collected prospectively from patients hospitalized in National University 
Hospital- a 900-bed acute care tertiary care hospital in Singapore, from April 12 2007 to 
October 30, 2008. Cases notified after October 12 2007 also formed a part of a clinical 
trial.  
2.1.1 Subjects for inclusion into the study 
Patients were included in the study if one or more blood culture grew Staphylococcus 
aureus. Positive blood cultures were notified to the investigator by the hospital 
microbiology laboratory. Patients were excluded if the bacteremia was polymicrobial or 
age of the patient was less than a year. Each patient was included only once in the 
dataset. Any recurrence of bacteremia during the study period from a patient who was 
already recruited was not included again. All patients who met the criteria during the 
duration mentioned above formed a part of the case series analysis of Staphylococcus 
aureus bacteremia.  
2.1.2 Subjects for inclusion in the clinical trial 
A Randomized controlled trial was started on October 12 2007. The Hospital’s 
Institutional Review Board had given approval for the study and the details of the trial are 
available on www.clinicaltrials.gov (NCT00622882).  The objective of the trial was to 
ascertain if an early infectious disease consultation (within 72 hours of notification of 
bacteremia) improved outcomes of patients of Staphylococcus aureus bacteremia. For 
this trial, consecutive subjects of Staphylococcus aureus bacteremia (as notified from the 





 Patient with a one or more blood culture positive for   Staphylococcus aureus  
 Age more than 1 year 
 Patient admitted in hospital 
Exclusion criteria 
 Recurrent bacteremia in a patient already recruited in the trial 
 Polymicrobial infection 
 Age less than one year 
 Patient not admitted in the hospital 
2.1.3   Trial workflow 
Figure 1 shows the workflow of the trial. Staphylococcus aureus bacteremia cases were 
notified to the single investigator (myself) by the laboratory. If the subject met the above 
criteria, they were randomised using a stratified block randomisation (Stratified by age 
cutoff of 65). Stratification was performed as various studies show that an older age 
group is associated with a higher mortality in patients with SAB. Subjects were 
randomised to one of the two arms as mentioned below 
• Intervention arm: Subjects in this arm would receive an early ID consultation 
subject to physician's consent 
• Control arm:  The clinical management in this arm would not be altered by an ID 
consultation, unless requested by the physician in care.  
We had obtained a consent waiver and hence before approaching the patient, only the 
primary physician’s consent was obtained.  The ID consultation involved a thorough 
history taking, examination and recommendation by a consultant. Phone consults were 
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not considered an ID consult. Before starting the trial, the ID consultants agreed upon a 
set management protocol. However, the final management of the patient was on the 
treating physician's discretion, which would decide whether the ID recommendations 
need to be followed or not.  
All cases recruited in this trial formed the dataset for the trial analysis and also the case 
series analysis. In addition, patients excluded from the trial analyses, which however, met 
the inclusion criteria for case series analysis were included.  
















Cases notified by the laboratory to single 
investigator (myself) 
Single investigator to check if cases meet 
the inclusion criteria 
Included cases were randomized using 
stratified block randomization into 
intervention or control arm 
Control arm: Chart review 
without interfering with the 
clinical care of patient 
Intervention arm: For those patients without 
an ID consultation for SAB at this point, 
primary physician’s verbal consent obtained 
for formal ID consultation 
After consent from primary physician, the 
ID consutant incharge for that ward for the 
particular day was informed and a formal 
consult ensured.  
Chart review begun  
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2.1.4    Chart review 
A single investigator (myself) reviewed the medical records and charts of the patient 
(from the case notes and the patient information system). The data was collected at the 
time of notification and then regularly till the discharge of the patient on a pocket PC (HP 
iPAQ rx 1950 series) with a database software namely, HanDBase® for Pocket PC 
Professional 3.51 Build 1. (Figure 2). The data was then synchronised from the pocket 
PC to a base computer and the data was exported and stored in an excel chart. Microsoft 
access was used to merge relevant databases.  
The relevant data included patient demographics, comorbidities, mode of acquisition, the 
source of bacteremia, vitals and comorbidity score (APACHE II and Charlson index), 
antibiogram of Staphylococcus aureus, MIC of every Staphylococcus aureus isolated 
from blood of each patient, relevant investigations, antibiotic details including the type, 
dose, route of administration and duration and the ID consultation details in particular the 
date, the recommendations and the adherence to recommendations. Certain data such as 
the hospital discharges and deaths in a year were collected from the Medical information 
systems available on the hospital intranet available to all staff.  
 
2.1.5 Outcome measures 
 
For the cohort and trial assessment, the primary outcome measure was mortality.  The 
secondary outcomes were   presence of metastatic infection, recurrence and 1-year 
mortality rate (based on review of patient information system). In addition for the trial, 




• Appropriateness of antibiotics 
• Follow up blood cultures 
• Echocardiography following SAB episode 
• Relevant radiological examination  
The relevant case definitions are given in the Table 3. 
Figure 2 HP POCKET PC with a sample of the HanDBase® database 











Table 3 CASE DEFINTIONS 
Profile 
Relevant case definitions 
Mode of 
acquisition 
Nosocomial bacteremia was defined if the positive blood culture was 
withdrawn 48 hours after hospitalization 
Community acquired bacteremia was defined as a positive blood 
culture withdrawn within 48 hours of hospitalization in a patient with 
no previous healthcare risk factors as defined below 
Healthcare associated bacteremia was defined as a positive blood 
culture withdrawn within 48 hours of hospitalization in a patient with 
the following healthcare risk factors; intravenous home therapy, 
hemodialysis, previous hospitalization in the last one year, nursing 
home resident, previous MRSA isolated in the last one year  
Primary source 
of bacteremia 
The source was determined by the presence of signs and symptoms of 
inflammation or isolation of Staphylococcus aureus at the site prior to 
the episode of bacteremia. When the source could not be determined, 
the bacteremia was considered as an unknown source or primary 
bacteremia 





Relevant parameters collected on the date of withdrawal of blood 
culture (64) 
Antibiogram 
An isolate was labeled as MRSA by standard microbiological 
techniques ie VITEK.MIC  to Vancomycin and other antibiotics was 
determined by VITEK 
Investigations 
TWBC and CRP data (if available) within 24 hours of time of 
withdrawl of blood culture was collected from the electronic medical 
information systems for the patient. Radiological and 
echocardiographic investigations was collected from the day of onset 




Note was taken from the date of notification to the date of ID 
consultation. Adherence to recommendations was considered if the 
antibiotics and the removal of source recommendations were adhered  
Antibiotic 
appropriateness 
Empiric antibiotic was considered appropriate if the organism 
isolated was sensitive to it.  
Appropriate definitive antibiotics was defined as follows 
1. IV cloxacillin (8gm/day) and iv cefazolin (6gm /day) were 
considered appropriate antibiotics for MSSA bacteremia 
2.Vancomycin (2gm/day or trough adjusted dose) was considered 
appropriate for MSSA only if the patient was allergic to penicillin 
3. Oral therapy with cloxacillin or quinolone/rifampicin combination 
was considered appropriate for MSSA if the patient was unable to take 
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IV or was keen to go home 
4. Vancomycin (2gm/day or trough adjusted dose) or oral/iv linezolid 
600mg twice a day was considered appropriate for MRSA 
5. A total duration of 10 days for uncomplicated infection and 4 weeks 
for complicated infection including endocarditis, persistent 




In-hospital mortality was defined as death during hospital stay. 
Patients who left against medical advice were not included in analysis.  
Secondary 
outcome 
An  extravascular site was considered a metastatic site if there were 
signs of inflammation /vegetation or isolation of Staphylococcus 
aureus during  or  after the development of bacteremia. This included 
endocarditis, bony sites for e.g., septic arthritis, vertebral 
osteomyelitis, discitiis, visceral sites such as the spleen, lung, brain 
and kidneys  
Recurrence was defined as a positive blood culture after resolution of 
signs of symptoms of bacteremia or after the receipt of appropriate 
antibiotics or after the documentation of negative blood cultures 
2.1.6   Statistical analysis 
Statistical tests were mainly used for  
 Predicting the risk factors for mortality (death versus discharge) 
 Predicting risk factors for metastatic infections (metastatic versus non metastatic 
infections) 
 Predicting the risk factors for mortality in MRSA bacteremia (MRSA death versus 
MRSA survivors) 
 Predicting risk factors and outcomes of a higher vancomycin MIC (Vancomycin 
MIC >2 vs. less than 2) 
 Predicting factors responsible for not getting a Transthoracic echocardiography ( 
those who got a TTE versus those who didn’t) 
 Comparing the baseline characteristics, standard of care and outcome in the 
randomized trial (intention to treat analysis, perprotocol and pretreatment, explained 
later in the results) 
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 Comparing the baseline characteristics and outcomes of different molecular clones of 
MRSA ( Spa type t037 and t032, explained later in results) 
For all categorical dependent variables, univariate categorical variables was analysed 
using the Chi-square test or the Fisher's exact test where needed and continuous variables 
were analysed by t-test or Wilcoxon rank sum test. Variables with a p value less than 0.05 
on univariate analysis were tested with multivariate analysis where needed in a stepwise 
estimation using multiple logistic regression. For all statistical analysis, significance was 
assumed at an alpha level of 0.05. Analysis was performed using STATA version 10 
(StataCorp, Texas, USA) 
2.1.7   Microbiological methods 
 
All blood cultures were processed with a commercial blood culture system ( BacT/Alert 
3D, Biomerieux, Durham, NC). Positive signals were then subcultured and reviewed after 
incubation for growth. If a colony was suspected to be Staphylococcus, it was speciated 
and confirmed as Staphylococcus aureus on the basis of a positive latex staphaurex 
agglutination and tube coagulase test. Every Staphylococcus aureus blood culture isolate 
was subjected to an antimicrobial susceptibility test using the VITEK method (which also 
records the MIC value for each antibiotic). The MIC values to serial Staphylococcus 








2.2 LABORATORY METHODS 
 
A subset of strains isolated from April 12, 2008 to 26 May 2008 was subjected to 
Staphylococcal Protein A (Spa) typing method as described below. 
Strains of Staphylococcus aureus were procured from the Hospital Microbiology 
laboratory and freezed at -80oC in glycerol BHI broths till further used. The steps of Spa 
(Staphylococcal Protein A) typing are elaborated below 
2.2.1 DNA extraction 
DNA was extracted from strains using the QIAGEN DNAeasy kit( Hilden, Germany). 
Briefly, a 1 ul loopful of growth was suspended in lysis buffer containing lysozyme and 
lysostaphin. After incubating at 37oC for 30 min, the lysed solution was treated with 
Proteinase K and ethanol before applying it to a column. The sample was then eluted 
after undergoing repeated washing steps in the column. More details on the methodology 
is available in Appendix 1 
2.2.2 Primer preparation 
The forward and the reverse primer used for spa typing is given below(150). 
 
Table 4 Primers used for PCR 
Primer Reference Primer sequence 
       Forward Primer 1095 F 5'-AGACGATCCTTCGGTGAGC-3' 
 




These primers were procured from a Commercial company (1st BASE, Singapore ) in a 
lyophilised form and stored at -20oC till further use.  100 µM stock solution of the primer 
was made according to the data sheet provided by the company supplying the primers. 
The primers were finally diluted and aliquoted as 10uM solutions for downstream PCR 
reactions. 
2.2.3 PCR Protocol 
PCR reagents were procured form QIAGEN (Taq PCR core kit, Hilden, Germany). The 
reaction master mix was set up in the proportions as given in the QIAGEN manual and 
are mentioned in Table 5. 1 µl of DNA was added to each of the reactions tubes. The 
cycling conditions as adopted by Shopsin and colleagues were used and are mentioned in 
Table 6(150)  .  
Table 5 Master mix for PCR reaction 
Reagents for Master Mix Volume per reaction, l (1X) 
Water 31.75 
10X PCR Buffer 5 
Q solution 10 
DNTP’s 1 
Forward Primer 1 
Reverse Primer 1 
Taq polymerase 0.25 
    
Table 6 Thermocycling conditions used for the PCR reaction 
  
No. of Cycles Steps Temperature (°C) Duration 
1X Initial Denaturation 95 10min 
Denaturation 95 45s 
*Annealing 52 30s 30X 
Extension 72 45s 
1X Final Extension 72 10min 
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The PCR products were resolved on a 1.5% agarose gel incorporated with ethidium 
bromide. 5ul of the PCR products were loaded on the gel and products were resolved at 
120V for 40 min. 
A negative control in the form of sterile water was included in each PCR run to ensure no 
contamination.  
2.2.4 Purification of PCR products 
The PCR products were purified using QIAGEN PCR purification kit (Hilden, Germany) 
or the QIAGEN Gel extraction kit (Hilden, Germany) depending on the number of DNA 
bands visualised. When more than one band was seen per sample, an additional 20ul was 
loaded and resolved on the gel and each band was then cut off the gel and purified. More 
details are given in Appendix 2 
2.2.5 DNA sequencing and analysis 
The purified PCR products were sent to a commercial company for DNA sequencing (1st 
BASE, Singapore). The samples were coded and anonymous in order to maintain 
confidentiality.  All the spa sequences were analysed using Bionumerics® Version 4.6. 
The variable region is analysed between two signature sequences (GCACCTAAA and 
TACATGTCGT as on the forward strand).   Bionumerics® uses the Ridom nomenclature 
which assigns numbers to each unique repeat (r01, r02, r03….) and spa type (t01, t02, 
t03, t04….). A cluster analysis was generated using the Minimum Spanning Tree (MST). 
MST chooses the sample with the highest number of related samples as the root node and 















RESULTS 1: EPIDEMIOLOGY AND OUTCOMES OF SAB 


















A total of 301 cases of SAB were notified by the laboratory from April 13, 2007 to 
October 30, 2008. These included 90 cases before the start of the trial on October 12, 
2007 and 211 cases after the start of the trial. One case was duplicated hence, 300 cases 
(which included only the first episode of bacteremia for the duplicate case) were part of 
the case series analysis. The overall SAB rate was 3.42/1000 discharges and deaths.  Of 
the 300 cases, 126 (42%) cases were attributed to MRSA and 174 (58%) to MSSA. The 
MRSA bacteremia rate was 1.44/1000 discharges and deaths. Figure 3 shows the 
monthwise distribution of all bacteremic cases. The highest numbers of cases were 
notified in January 2008 (n=24) and the lowest in May 2007 (n=7). There was no 
observable seasonal distribution of cases.  

































































































                                  
3.2 Age and sex distribution  
The median age of patients was 58 (IQR: 21-73, range: 1-96) with 180 (60%) cases of 
SAB in males and 120 cases (40%) in females. Female patients and MRSA bacteremic 
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cases were older in comparison with males (median age: 61 vs. 56, p=0.03) and MSSA 
bacteremia (median: 64 vs. 54, p value=0.004) respectively. 
 Figure 4 shows the age distribution of SAB cases and MRSA cases in males and 
females. Overall, a male preponderance is observed in all age groups except the extreme 
age groups (more than 80 and less than 20).  As seen in Table 7, there is an unequal 
distribution of cases across different specialities and this could possibly explain the male 
preponderance. The median age for MRSA bacteremic women was 68 (IQR: 55-78) vs. 
62(IQR: 51-71) for males (p value: 0.07).                                  




































3.3 Distribution in different disciplines 
Table 7 shows the distribution of SAB in different disciplines. 234 (78%) of the cases 
were admitted in the medical wards at the time of bacteremia as compared to 66 (23%) in 
the surgical wards.  Majority of the cases as expressed in numbers were admitted in 
Cardiothoracic vascular surgery, nephrology, oncology, general medicine, respiratory 
medicine and cardiology.  
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The proportion of cases caused by MRSA varied in the medical and surgical disciplines 
(35.8% vs. 63% p value<0.001, OR:0.3 CI95:0.2-0.6} The rate of MRSA bacteremia/1000 
discharges and death was highest in the orthopedics cases with  6.56 cases /1000 
discharges/death.  










Otorhinolaryngology 1 0.92 1 0.92 
Plastic surgery 2 2.48 2 2.48 
Urology 2 1.20 1 0.60 
Geriatric medicine 3 6.98 0 0 
Hepatobiliary medicine 3 2.34 3 2.34 
Colorectal surgery 3 1.21 3 1.20 
Trauma 3 3.43 3 3.43 
Rheumatology 3 6.74 1 2.25 
General surgery 5 1.87 4 1.50 
Neurosurgery 5 2.23 3 1.34 
Spinal surgery 5 3.58 2 1.43 
Infectious Diseases 6 27.65 0 0 
Endocrine medicine 8 6.48 3 2.43 
Gastroenterology 8 2.94 4 1.46 
Pediatrics 11 1.78 0 0 
Cardiothoracic vascular 
surgery 
17 7.29 13 5.57 
Orthopaedics 21 13.79 10 6.56 
Cardiology 25 2.97 9 1.07 
Respiratory 27 6.81 11 2.77 
Hematoloy/oncology 30 7.41 15 3.70 
Nephrology 53 17.25 17 5.53 
General  medicine 57 6.79 21 2.50 
Dermatology 1 83.3 0 0 
Dental medicine 1 58.8 0 0 
Total 300 3.42 126 1.44 
 
3.4 Mode of acquisition 
In our case series of 300 cases, 122 (41%) were healthcare associated, 113 (38%) 
nosocomial and 64(21%) community-acquired infections (Figure 5). The mode of 
acquisition of one case of MRSA bacteremia was not known.  Among the healthcare 
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associated infections 50/122 (40.9%) were receiving hemodialysis and 78/122 (63.9%) 
patients had a hospitalization in the three months prior to bacteremia. The time from the 
date of admission to the onset of bacteremia for nosocomial infections ranged between 2-
132 days (Figure 6). Almost 50% of the nosocomial SAB had the episode between 2-8 
days of hospitalization.  
IVDU was the risk factor in   27 of the 64 (42%) of the community acquired infections 
and all these strains were MSSA.  An additional 18 of the 64 (28%) community acquired 
SAB had comorbidities in the form of diabetes (9), renal failure (5), structural heart 
disease (3), blood disorder (2) and history of orthopedic implants (1). No specific risk 
factor could be identified in 19 (30%) of the cases.   
The proportion of cases attributable to different modes of transmission varied in the 
MRSA and MSSA cohort. Of the 125 MRSA and 174 MSSA cases, 81 (64%) vs. 
32(18.3%) were nosocomial, 41(32.5%) vs. 81(46.5%) healthcare associated and 3 
(2.3%) vs. 61 (35.2%) community acquired respectively. The difference in the 
proportions of nosocomial and community infections caused by MRSA and MSSA was 
statistically significant (MRSA vs. MSSA: for nosocomial   71 %vs. 28%, for community 
4.6 %vs. 95% p value <0.001) (Figure 5).   
Similar difference of proportions was seen among patients admitted in the medical and 
surgical wards. Surgical patients were more likely to have a nosocomial infection. In 
contrast, all three modes of transmission were equally represented among the patients 



















Figure 6:  Timing of nosocomial infection 
 
3.5 MRSA profile 
Figure 7 and 8 below shows the antibiotic resistance of MRSA.  Notably the resistance to 
ciprofloxacin and erythromycin exceeded 90% while the resistance to clindamycin, 
cotrimoxazole and gentamicin was between 60-70%. We do not have data on the 
dissociative resistance to erythromycin and clindamycin.  No strain showed a frank 
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resistance to vancomycin when tested by the routine microbiological methods. However, 
21% of the strains showed a MIC of 2 or 4.  
Figure 7:  Antimicrobial resistance profile of MRSA 

























































Figure 8:   Vancomycin MIC distribution among MRSA (n=126) 























3.6 Risk factors 
Around 95% of the case series cohort had presence of one or more risk factors. These 
included previous surgery (83/27%), previous hospitalization (224, 74%), foreign 
implants (24, 8%), presence of long lines (83/27%), IV drug abuse (32/10%) and 
comorbidities in particular diabetes (129,43%), malignancy (49,16%), structural heart 
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disease (41, 13.6%), chronic liver disease (18, 6%), chronic renal disease (103, 34%), 
blood disorders (18, 6%), connective tissue disorder (123,4%), COPD (15,5%) and 
pneumonia (47,15%). Two or more risk factors were present in 81% of the cohort. 
No identifiable comorbidity was present in 11.6% of the cohort. Among the rest, a single 
comorbidity was present in 36% (107), two comorbidities in 36%( 109) and three or more 
comorbidities in 16% (49) of the cohort.  
3.7 Portal of entry (Source of bacteremia) 
The source of bacteremia was unknown or primary bacteremia in 36% (107/300) of the 
cases. The commonest observable source was a line source in 25% (75/300) of patients. 
The line infection represented a CVC line in 69 cases and a peripheral intravenous line in 
6 cases. The other sources were superficial skin source in 19% (58/300) cases, deep tissue 
source including septic arthritis, mediastinitis and pyomyositis in 14% (43/300) and a 
lung source in 5%(14/300) cases. In two patients a combined source was suspected. This 
included pneumonia in both patients in addition to a sacral source and a CVP line 
infection.  
3.8 Outcome at a glance 
Of the 300 cases, the outcome of 10 patients was unknown as they were discharged 
against medical advice (n=10).  Of the remaining 290 cases, 201 (69.3%) patients were 
discharged after an improvement in the condition, 85(29.3%) died during the hospital 
stay, 3 were transferred to another healthcare after two weeks stay in the hospital (15,17 
and 18 days) and 1 patient was still in hospital. Among those discharged, 17 patients 
(17/201; 8.5%) subsequently died within a year of the bacteremic episode.  
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3.9 Mortality profile 
The crude in-hospital mortality rate was 29.3%. The 7 -day, 30- day and 60- day 
mortality was 41/294 (13.9%), 74/293 (25.3%) and 85/291(29.2%) respectively. One year 
crude mortality rate could be evaluated at the end of 2008 for the cohort of patients 
presenting with bacteremia in the year 2007. The 1-year mortality rate in this cohort was 
33 %( 44/133). 
Of the 85 in hospital deaths, 53/85 (62.4%) had MRSA bacteremias.  Eighty seven 
percent (74/85) of the deaths were in patients with previous or ongoing healthcare 
exposure (also classified as nosocomial and healthcare associated infection). The time 
from the onset of bacteremia to death ranged from 1- 156 days. Approximately 20% of 
the deaths took place in the first 2 days, 40% in the first 4 days and 80% within 21 days 
of bacteremia (Figure 9). 
For analyzing the predictors of in-hospital mortality, we compared 85 such patients with 
201 patients who were discharged after the bacteremic episode. Table 8 and Figure 10   
shows the results of this analysis. In univariate analysis, patients who died were older 
(median: 71 vs. 54, p value <0.01) and more ill as suggested by a higher Charlson 
(median: 6 vs. 4, p value <0.01) and higher APACHE II score (median 16 vs. 12, p 
value<0.01).  Other predictors of mortality were MRSA infection (OR 3.34, CI95: 1.97-66 
p value <0.01), ICU stay (OR 2.4 CI95:1.29-4.46, p value <0.01), chinese ethnic group (p 
value<0.05), nosocomial infection (p value<0.05), source such a lung (p value<0.05), 
malignancy (OR 2.28 CI95: 1.2-4.36, p value=0.01), persistent bacteremia (OR 2.77 CI95: 
1.32-5.85, p value=0.01), history of widespread skin disease (OR 3.3 CI95: 1.64-6.74 
p=0.001) and pneumonia (OR 3.98 CI95: 2.07-7.66, p value < 0.01).   
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For the multivariate analysis, all the above-mentioned significant factors were included 
except persistent bacteremia (as this data was not available for patients who died in the 
first 48 hours of bacteremia), ethnicity, IVDU and an ICU stay ( as we limited the 
numbers of factors analysed to 8 or less owing to small numbers of outcome measures  
i.e. 85 deaths). Using the multiple logistic regression, the predictors of in-hospital 
mortality were age (p value<0.001), MRSA infection (p value=0.002), malignancy 
(p=0.002), history of skin disease (p value <0.001) and Apache score ( p value =0.008).  
A skin and line source was associated with lower mortality when compared to unknown 
source as a reference (line source, p value=0.04, skin source, p value=0.022) 






Figure 10: Age, APACHE Score, Charlson index for patients who died versus 
survivors 
      
                                                  
            





Figure 10a: Age distribution of patients who died vs. those who survived 
Figure 10b: Charlson score of those who died vs. survived 






Table 8 Analysis of predictors of all cause in hospital mortality 
 
 




ODDS RATIO P VALUE 






Male 122(60.80) 49(57.65) 0.88(0.52-47) 0.62 
MRSA 66(33.17) 53(62.35) 3.34(1.97-66) <0.001(=0.002) 
Chinese vs. Malay 114(56.28) vs48 (24.12) 63(74.12) vs. 14(16.47) 0.52(0.27-1.03) 
 
0.06 
Mode of acquisition    0.02‡ 
Community vs. Nosocomial  49(24.12) vs. 66(33.17) 11(12.94) vs. 42(49.41) 2.84(1.32-6.06) 
 
0.007 
Community vs. Healthcare 
associated 
49(24.12) vs. 85(42.71) 11(12.94) vs. 32(37.65) 1.67(0.77-3.62) 
 
0.188 
Source of bacteremia    0.001‡ 
Unknown vs. Superficial skin  70(34.8) vs. 42(20.9) 34 (40) vs. 12(14.1) 0.58(0.27-1.25) 
 
0.17(=0.022) 
Unknown vs. Deep tissue source 70(34.8) vs. 30 (14.9) 34 (40) vs. 10(11.8) 0.68(0.30-1.56) 
 
0.37 
Unknown vs. Line source 70(34.8) vs. 55(26.4) 34 (40) vs. 17(20) 0.63(0.32-1.25) 
 
0.19(=0.04) 
Unknown vs. Other sources  70(34.8) vs. 4(2) 34 (40) vs. 12(14.1) 6.17(1.85-20.5) 0.003 
IV drug abuse 27(13.07) 3(3.53) 0.24(0.07-0.83) 0.02 
Diabetes 
 






*Denotes median and  IQR for continuous variables, † Denotes the odd ratio for every unit change, for example, in this analysis a person 10 year older , would 







ODDS RATIO P VALUE 
Uni ß(multi γ ) 
Malignancy 
25(12.56) 21(24.71) 2.28(1.20-4.36) 0.01(=0.002) 
Liver disease  
13(6.53) 5(5.88) 0.89(0.31-2.59) 0.84 
Renal disease  
71(35.68) 28(32.94) 0.89(0.52-1.52) 0.66 
Pneumonia 
20(9.95) 26(30.59) 3.98(2.07-7.66) 0.04 
H/O skin disease 
17(8.46) 20(23.53) 3.33(1.64-6.74) 0.001(<0.001) 
Charlson index 
4(2-6) 6(4-7.5)  <0.01 
Apache Score 
12(8-16)* 16(12-21)* 1.12(1.07-1.17)† <0.01(0.008) 
Persistent fever 
37/179(20.67) 12/49(24.49) 1.24(0.59-2.62) 0.56 
Persistent bacteremia 
28/173(16.18) 15/43(34.88) 2.77(1.32-5.85) 0.01 
Metastatic infections 
42/181(23.2) 16/50(32) 1.55(0.78-3.09) 0.204 
Appropriate empiric antibiotic 
96/185(51.89) 28/68(41.18) 0.61(0.34-1.08) 0.13 
Appropriate  definitive  antibiotic 
114/179(63.96) 35/56(62.5) 0.91(0.48-1.74) 0.87 
Surgical intervention following 
SAB 





3.10 Metastatic infections 
In patients with a length of stay (LOS) longer than 4 days (n=240), 61(25.4%) patients 
had one or more metastatic sites of infection. This included metastasis to a single site or 
multiple sites in 38 (16 %) and 23(9%) of patients respectively (Figure 11).  
Figure 11: Metastatic infections in Staphylococcus aureus bacteremia (n=240) 











Infective endocarditis was the commonest metastatic infection diagnosed in 35/ 240 
patients (14.5%), followed by bony site (24/240,10%), visceral infection (23/240,9.5%) 
and soft tissue and muscle infection (n=9, 3.7%). The visceral metastatic sites included 
lung (14), kidney (7), Spleen (3), brain (3) and liver (2)(Figure 12).  
Figure 13 shows the distribution of metastatic infections in MSSA and MRSA 
bacteremia. Of the 35 infective endocarditis cases, 28 were attributable to MSSA. While 
endocarditis and visceral metastatic infections were more common in MSSA( p value : 
0.003 and 0.01 respectively) , bony metastatic infections were equally common in MSSA 
or MRSA bacteremia( p value =0.8).                 
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Figure 12: Breakdown of the metastatic infection sites 
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The in hospital mortality was 20.5% among all patients with IE ( 7/35).  This included 5 
cases of MSSA IE and 2 of MRSA IE. TTE (Transthoracic echocardiography) detected 
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vegetations in 29 /33 IE patients who underwent this procedure. TEE (Transesophageal 
echocardiography) could detect vegetations (one on mitral valve and one on aortic) in 2 
of the 4 TTE negative IE patients.  
For analyzing the predictors of metastasis, 61 patients with metastasis were compared 
with 179 patients with non-metastatic bacteremia. (Table 9). On a Univariate analysis, 
younger age (Median: 47 vs. 60 p value=0.03), ethnicity (p value=0.017), MSSA 
infection (OR 2.55 CI95:1.36- 4.81, p value=0.004), Community acquisition (p value: 
<0.001), IV drug abuse (OR: 37.12 CI95: 12.21-112.83, p value: <0.001), Lower Charlson 
index (median 2 vs. 4, p value =0.001), unknown source, higher CRP (median 206 vs. 
123 p value<0.001), persistent bacteremia (OR: 2.85 CI95: 1.42-5.74 p value=0.003) and 
longer duration of symptoms before the detection of bacteremia (median 4 vs. 2, p 
value=0.022) were significant at PC 0.05. Renal disease (OR: 0.42 CI95: 0.2-0.85, p 
value=0.01) and malignancies (OR=0.21CI95: 0.06-0.69, p value=0.01) were less 
commonly associated with metastasis. For multiple logistic regression, all factors with a p 
value of less than 0.05 were included with the exception of CRP as the data was missing 
for many patients and age, duration of symptoms before presentation to hospital, renal 
disease and malignancy.  The predictors of metastasis in this analysis were IVDU(<0.01) 
and persistent bacteremia(p=0.004).   
3.11 Recurrence 
Out of 201 discharges, recurrent bacteremia was encountered in 20 cases (9.9%). The 
time to recurrence varied from 16 to 460 days. In 5 cases, the recurrent strain was MRSA 
while the original bacteremia was due to MSSA.  
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Table 9 Analysis of predictors of metastatic infections 
  

















Male 110(61.45) 39(63.93) 01.11(0.61-2.03) 0.73 
MRSA 89(49.72) 17(27.87) 0.39(0.21-0.73) 0.004 
Chinese vs. Malay 117(65.36) vs. 37(20.67) 31(50.82) vs. 17(27.87) 1.73(0.86-3.48) 
 
0.122 
Mode of acquisition    <0.001 ‡ 
Community vs. Nosocomial  
 
26(14.61) vs. 79(44.38) 31(50.82) vs. 15(24.59) 0.159(0.074-0.34) 
 
<0.01 
Community vs. Healthcare 
associated 




Source of bacteremia    0.001‡ 
Unknown vs. Superficial skin  45(25.14) vs. 45(25.14) 
 





Unknown vs. Deep tissue 
source 
45(25.14) vs. 32 (17.88) 
 





Unknown vs. Line source  45(25.14) vs. 50(27.93) 
 





IVDU 4(2.23) 28(45.90) 37.12(12.21-112.83) <0.001(<0.001) 
Haemodialysis 40(22.35) 10(16.39) 0.68(0.32-1.46) 0.32 
Malignancy 36(20.11) 3(4.92) 0.21(0.06-0.69) 0.01 
Renal disease  62(34.64) 11(18.03) 0.42(0.20-0.85) 0.01 






*Denotes median and IQR for continuous variables, † Denotes the odd ratio for every unit change, for example, in this analysis a person 10 year younger, would 
















Uni ß (Multi γ) 





















Persistent fever 32/161(19.88) 16/571(28.07) 1.57(0.78-3.15) 0.20 
Persistent bacteremia 23/151(15.23) 20/59(33.90) 2.85(1.42-5.74) =0.003(0.004) 
Duration of symptoms 2(1-4)* 4(2-7)*  0.02 





3.12 Outcomes and predictors of MRSA bacteremia 
The outcomes of patients who died subsequent to the detection of   MRSA bacteremia 
(n=53) were compared with those who survived (n=67) and were discharged after an 
improvement (Table 10). On a univariate analysis, mortality rate was higher in elderly 
age (OR: 1.04 CI95::1.02-1.07, p value <0.001), female sex (OR: 2.09 CI95::0.98-4.44 , p 
value=0.05), those with a higher APACHE II score (OR: 1.12 CI95::1.05-1.21, p 
value<0.001), higher Charlson index (OR: 1.26 CI95::1.09-1.45, p value<0.001) and 
having bony metastatic infection (OR: 4.99 CI95::1.20-20.69, p value =0.02). However, 
on a multivariate analysis, none of the above mentioned factors were significant.  
3.13 Outcomes of higher vancomycin MIC among MRSA isolates  
Out of 126 MRSA isolates, a vancomycin MIC of 2 or above was seen in 27(21.4% of all 
MRSA) isolates. Of these, only one isolate was a frank VISA with an MIC of 4. Twenty 
one isolates showed a rise in MIC from <1 to 2. A univariate analysis for outcomes and 
risk factors for a higher MIC (2 or above)  (n= 27) as compared with an MIC of<=1  (n= 
98) showed that patients with a higher vancomycin MIC were more likely to have a line 
source (OR: 8.90, p value: 0.009), deep tissue source (OR: 6.2, p value= 0.035), 
hemodialysed (OR: 3.25 CI95::1.25-8.46, p value=0.012) and more likely to encounter 
persistent bacteremia (OR 4.75 CI95::1.76-12.6, p =0.001), bony metastatic infections 
(OR: 6 CI95::1.53-23.4, p value: 0.03) and blood recurrences (OR: 5.34 CI95::1.32-21.5, p 
value=0.01).  For analyzing the outcome further, bony metastatic infections, blood 
recurrences and persistent bacteremia were analysed by a multivariate logistic regression. 
In this model, only persistent bacteremia and bony metastasis were more likely in patients 
with a higher MIC ( Table 11 )  
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Table 10 Predictors of mortality of MRSA bacteremia 




ODDS RATIO  
 ( CI95) 
 
P VALUE 






Male 47(70.1) 28(52.8) 0.48(0.22-1.01) 0.05 
ICU stay 13(19.4) 16(30.2) 1.80(0.77-4.17) 0.17 
Chinese vs. Malay  44(65.7) vs. 
16(23.9) 
40(75.5)vs. 9(17.0) 0.61(0.24-1.55) 
 
0.31 
Mode of acquisition    .48‡ 
Community vs.  Nosocomial   2(3.0) vs. 39(59.1)  1(1.9) vs. 37(69.8)  1.89( 0.17-21.8) 
 
0.60 
Community vs. Healthcare associated 2(3.0)vs. 25(37.9) 1(1.9) vs. 15(28.3) 1.2( 0.1-14.3) 
 
0.88 
Source of bacteremia    0.25‡ 
Unknown vs. Superficial skin source 16(23.9) vs. 4(20.9) 15(28.3) vs. 8(15.1) 0.61( 0.2-1.86) 
 
0.38 
Unknown vs. Deep tissue Source 16(23.9) vs14(20.9) 15(28.3) vs. 7(13.2) 0.53(0.16-1.68) 
 
0.28 
Unknown vs. Line source 16(23.9) vs20(29.9) 15(28.3) vs. 15(28.3) 0.8(0.3-2.1) 
 
0.65 
Unknown vs. Others 16(23.9)  vs. 3(4.5) 15(28.3) vs. 8(15.1) 2.8(0.63-12.7) 
 
0.17 



















ODDS RATIO  
 ( CI95) 
 
P VALUE 
Uni ß(multi γ ) 
Diabetes 28(41.8) 28(52.8) 1.56(0.76-3.22) 0.23 
Hemodialysis 13(19.4) 12(22.6) 1.22(0.50-2.94) 0.66 
Malignancy 12(17.9) 16(30.2) 1.98(0.84-4.67) 0.11 
Lliver disease 3(4.5) 3(5.7) 1.28(0.25-6.62) .77 
Renal disease 20(29.9) 19(35.8) 1.31(0.61-2.83) 0.49 
Pneumonia 9(13.4) 14(26.4) 2.31(0.91-5.87) 0.07 
H/O skin disease 5(7.5) 8(15.1) 2.22(0.51-9.76) 0.18 










Persistent fever 15(23.8) 8(25.0) 1.07(0.40-2.87) 0.90 
Persistent bacteremia 16(26.2) 12(42.9) 2.11(0.82-5.41) 0.12 
Metastatic infections 8(12.3) 8(22.2) 2.04(0.69-5.99) 0.19 




*Denotes median and  IQR for continuous variables, † Denotes the odd ratio for every unit change, for example, in this analysis a person 10 year older , would 













ODDS RATIO  
 ( CI95) 
 
P VALUE 
Uni ß(multi γ ) 
Visceral metastasis 2(3.1) 1(2.8) 0.90(0.08-10.28) .93 
Bony metastasis 3(4.6) 7(19.4) 4.99(1.20-20.69) .02 
Higher Vancomycin MIC ( >2) 10(15.2) 15(28.3) 2.21(0.89-5.43) 
 
0.08 
Appropriate empiric antibiotic 29(48.3) 14(38.9) 0.77(0.34-1.72) 0.37 
Appropriate definitive antibiotic 43(75.4) 20(64.5) 0.71(0.29-1.73) 0.28 
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Table 11 Predictors and outcomes of a high vancomycin MIC value 
 VANCOMYCIN MIC 2 OR 
ABOVE 
(n=27) 
VANCOMYCIN MIC 1 
OR BELOW 
(n=98) 
ODDS RATIO P VALUE 
Uni ß(multi γ ) 
Age 64(52-74)* 60(51-70)* .99(.96-1.01)† 0.53 
Male Sex 18(66.8) 60(61.2) 1.26(0.51-3.10) 0.61 
ICU Stay 7(25.9) 22(22.45) 1.20(0.45-3.23) 0.71 
Chinese vs Malay 19(70.37) vs 7(25.9) 69(70.4) vs 19(19.4) 1.33(0.49-3.6) 0.57 
Healthcare associated infection 18(66.7) 63(64.5)  0.65‡ 
Nosocomial infection 9(33.5) 32(32.65)  0.65‡ 
Source of bacteremia    0.009‡ 
Unknown vs. Superficial skin source 2(7.4) vs. 3(11.1) 28(28.8) vs. 21(21.7) 2(0.3-13.06) 0.46 
Unknown vs. Deep tissue source 2(7.4) vs. 7(25.9) 28(28.8) vs. 16(16.5) 6.12(1.13-33.1) 0.035 
Unknown vs. Line infection 2(7.4) vs. 14(51.9) 28(28.8) vs. 22(22.7) 8.9(1.82-43.3) 0.007 
Unknown vs Other source 2(7.4) vs. 1(3.7) 28(28.8) vs. 10(10.3) 1.4(0.12-17.2) 0.79 
Diabetes 17(62.9) 42(43.3) 2.22(0.92-5.35) 0.07 
Haemodialysis 10(37.04) 15(15.31) 3.25(1.25-8.46) 0.012 
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*Denotes median and  IQR for continuous variables, † Denotes the odd ratio for every unit change, for example, in this analysis a person 10 year older , would 
have an odds of 1.0510 times that of the younger, ‡ 
 VANCOMYCIN MIC 2 OR 
ABOVE 
(n=27) 
VANCOMYCIN MIC 1 
OR BELOW 
(n=98) 
ODDS RATIO P VALUE 
Uni ß(multi γ ) 
Malignancy 7(25.9) 23(23.7) 1.12(0.42-2.99) 0.812 
Liver disease 1(3.7) 5(5.10) 0.71(0.08-6.39) 1 
Renal disease 12(44.4) 28(28.57) 2(0.83-4.80) 0.117 
Apache score 14(11-19)* 13(10-18)* 0.99(0.92-1.07)† 0.93 
Charlson score 5.5(3-8)* 4(3-6)* 1.14(0.98-1.33)† 0.08 
Persistent bacteremia 14(58.3) 16(28.6) 4.75(1.76-12.6) 0.001(0.009) 
Persistent fever 7(30.4) 17(22.9) 1.46(0.51-4.15) 0.49 
All metastatic site infection 7(28) 10(12.5) 2.72(0.90-8.14) 0.06 
Infective endocarditis 2(8) 5(6.25) 1.30(0.23-7.17) 0.75 
Visceral metastatic infection 1(4) 3(3.75) 1.06(0.10-10.7) 0.95 
Bony metastatic infection 6(24) 4(5) 6(1.53-23.4) 0.01(0.03) 
Overall in-hospital mortality 15(60) 38(40.5) 2.21(0.89-5.43) 0.08 
Blood recurrences 5(18.5) 4(4.1) 5.34(1.32-21.5) 0.01 
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3.14 Outcomes depending on the standard of care 
The following standard of care was evaluated for our cohort of patients 
 ID consultation 
 Antibiotic appropriateness 
 Follow up blood cultures 
 Echocardiography following an episode of SAB 
 Removal of source in particular line infection 
3.14.1 ID Consultation details 
Full details of whether an ID consultation took place before or after an episode of SAB was 
available for 264/300 (88%) cases. One hundred and eighty (180/264= 68%) patients had an ID 
consultation after the detection of SAB. Eighty four cases (84/264= 31.8%) never had an ID 
consult during the hospital stay after the detection of SAB.  
An ID consult took place within the first 72 hours of notification in 163/180 cases (90.5%) and 
within 48 hours in 160/180 (88%) cases. The ID recommendations were adhered in 156/180 
(87%) cases while the recommendations were not followed in 21/180 (11.6%) cases.    The crude 
mortality was 23.7 % and 27.3% for patients who received and ID consultation within 72 hours 
and followed the recommendations versus those who did not receive an ID consultation 
respectively (OR: 0.82(0.45-1.51), p value: 0.63) 
In order to understand the impact of an ID consultation, a randomized trial was undertaken, the 
interim results of which are elaborated in a later section.  
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3.14.2 Antibiotic details 
Empirical antibiotic details were available in 263 cases. Appropriate empirical antibiotics were 
instituted in 48.6% of the cases. MRSA or MSSA bacteremia cases were equally likely to receive 
appropriate empirical antibiotics (44.4 vs. 51.6 %, p value =0.32). As per the criteria laid down, 
63.6% of our patients received appropriate definitive antibiotics. MRSA bacteremia patients 
were more likely to receive appropriate definitive antibiotics than MSSA bacteremia (71.3 vs. 
58.2%, p value=0.024). (Figure14)  
Among patients not receiving appropriate empirical antibiotics (n=125), 12 patients did not 
receive any antibiotics at all (8%), 13 received oral antibiotics (10.4%) and the remaining 
patients received intravenous antibiotics such as ceftriaxone, augmentin, pipercillin/tazobactam, 
imipenem, meropenem, ciprofloxacin or ceftazidime.   
In patients not receiving appropriate definitive antibiotics, 18 patients received an inappropriate 
class or route of administration, 41 received the correct class, however in an inadequate dosage 
and 29 patients received antibiotics for a duration less than that recommended for their 
bacteremia.  
The outcome in terms of mortality was similar in patients who received appropriate 
empiric/definitive versus those who did not receive appropriate antibiotics. (Table 8) 
3.14.3 Removal of line source 
Data on the removal of lines was available from 54/61 line infection cases. The implicated line 




One hundred and eighty patients of SAB (60%) underwent an echocardiographic evaluation for 
presence of vegetations. All these patients had a Transthoracic echocardiography (TTE); 
however, 14 patients additionally (14/180) underwent a transesophageal echocardiography( TEE)  
later in the course of infection. In these patients, TEE was able to pick up 2 additional cases of 
endocarditis, which were negative by TTE.  
On a univariate analysis patients with nosocomial or healthcare associated infection (p=0.001), 
pneumonia (p=0.035), hemodialysis (p=0.003), malignancies (0.018), renal disease (p=0.016), 
shorter length of stay (mean 9.6 vs. 31.2, p =0.0002) and patients admitted under medical units 
(p=0.004) were less likely to have a follow up TTE. On a multivariate analysis, patients with a 
length of stay of less than 4 days (p<0.01) and nosocomial bacteremias (p value=0.025) were less 
likely to undergo a TTE. 
3.14.5 Follow up blood cultures 
 For those with an LOS >= 4 days, 68%(143/253) had a follow up blood culture 2-4 days 
following the bacteremia. Of the remaining 107 patients, 70 patients had a follow up blood 
culture early on (1 day after the bacteremia) or within 7 days of bacteremia or both.  
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Figure 14: Antibiotic characteristics 












































RESULTS 2: A RANDOMISED CONTROL TRIAL OF ID 




















An IRB (Institution Review Board) approved trial recruiting patients with Staphylococcus 
aureus bacteremia began on October 12, 2007. The purpose of the trial was to determine 
if an ID consultation improved outcomes of patients with SAB.  
A total of 211 patients had SAB episodes from Oct 12, 2007 to Oct 30 2008. Of these 184 
were recruited in the trial.  Twenty seven patients were excluded because of death at the 
time of notification (n=14), patients were not in hospital (n=3) or patients were missed 
due to investigator factors in the trial (n=10).  
The patients eligible for the trial were randomized to an ID consult or the control arm by 
stratified block randomization. Of the 184 patients eligible in this study, 93 were 
allocated to an ID consult while 91 were allocated to the control arm. Of those in the ID 
arm (n=93), the outcomes of 72 patients were finally analysed as others were lost to 
follow up ( n=4) , were on supportive care ( n=11)  or the physician refused the patient to 
be included in the trial ( n=6).  Of the 91 patients in the control arm, 83 were finally 
analysed as 1 patient was lost to follow up and 7 were on supportive care (Figure 15).  
We performed three types of trial analysis as mentioned below.  
 Per-Protocol analysis: We compared patients in the ID arm who received the ID 
consult within 72 hours vs. patients in the control arm who did not receive the ID 
consult. Out of 83 patients in the control arm, 43 patients received ID consult later 
hence the remaining 40 patients were compared with 70 patients in the ID arm (2 
patients in the ID arm did not receive an ID consult within 72 hours) 




Figure 15: Details of randomized controlled trial 
 
                                         
 
Assessed for 
eligibility  (n= 211) 
Allocated to ID arm 
(n= 93) 
Allocated to Control arm     
(n= 91  ) 
Refusal =6 
DNR status =11 
Lost to follow-up =4  
  
 








  Excluded  
• Death (n=14) 
• Not in hospital  (n=3) 
• Missed (n=10) 
Received ID consult=70 
 
NO ID: 2 
 
Did not receive ID consult=40 
 
Received ID: 43  
     : Included for intention to treat analysis       : Included in perprotocol analysis    
      : Pertreatment analysis 
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 Intention to treat analysis: We analysed the ID arm (n=72) and the control arm 
(n=83) irrespective of whether the patient had the ID consult 
 Pertreatment analysis: We compared all patients who received an ID consult 
(n=113) vs. those who did not receive an ID consult (n=42). An ID consult was 
deemed to have taken place only if the patient had a consult in the first 72 hours of 
notification. Any consult after 72 hours was taken as NO ID Consult.  
4.1 Per-protocol analysis 
Patients in the control arm were more likely to have higher APACHE II score (median: 
15 vs. 13,p value =0.01), hemodialysed (OR: 2.26, CI95::1.00-5.07 p value=0.05) and 
admitted under medical specialties (OR: 5.62 CI95:: 1.2-25.9, p value=0.01) as compared 
to the ID arm.  Standard of care varied in both arms. Patients in the ID arm were more 
likely to receive a transthoracic echocardiography (OR: 3.91 CI95:: 1.71-8.92, p 
value<0.01), Appropriate definitive antibiotics (OR: 7.81 CI95::3.02-20.24, p value<0.01) 
and surgical intervention (OR: 15.6, CI95::2.01-121.37 p value=0.009) for SAB episode. 
However outcome did not vary appreciably. Overall mortality was 19 vs. 10%, blood 
recurrence 5.7 vs. 15% in the ID and control arm respectively (Table 12). On a 
multivariate analysis for the process measures, appropriate definitive antibiotics (<0.001) 
and a surgical intervention (p value=0.042) was different in both groups (Table 12). 
4.2 Intention to treat analysis 
The profile of patients   was similar in the ID and control arms.  The age, sex, mode of 
acquisition, source of infection, comorbidities and comorbidity scores were equally 
represented in both groups. The outcomes were also similar in both the groups. Crude in 
hospital mortality was 20 vs. 14%, blood recurrences 5.5 vs. 11% and persistent 
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bacteremia 20 vs 21% in the ID and control groups respectively. The standard of care was 
also similar in both the groups with the exception of surgical intervention. Patients in the 
ID arm had more surgical interventions (29% vs. 16%), however, this did not reach 
statistical significance (p=0.068)(Table 13) 
4.3 Pertreatment analysis 
On a univariate analysis, patients from surgical units (OR 0.2 CI95::0.06-0.71, p value 
=0.01), community acquired infection (p value=0.01) IV drug abusers (OR: 8.82 
CI95::1.14-67.92, p value=0.02) and Infective endocarditis (OR: 3.36 CI95::0.95-11.85, p 
value=0.05) were more likely to have ID consults, while patients with higher Apache 
(median 15 vs. 12, OR: 0.92 CI95::0.87-0.98 p value=0.008) and lower Charlson score 
(median: 3 vs. 4.5, OR: 0.87 CI95::0.77-0.99 p value=0.047), hemodialysis (OR: 0.27 
CI95::0.12-0.57, p value<0.01) and renal disease (OR: 0.31 CI95::0.15-0.66, p value<0.01) 
were less likely to have an ID consult. Transthoracic echocardiography (OR: 5.84 
CI95::2.7-12.66, p value<0.01), Radiological imaging (OR: 2.8 CI95::1.01-7.77, p 
value=0.04), Surgical intervention (OR: 7.9 CI95::1.8-34.64, p value<0.01) and 
appropriate antibiotics (OR: 10.54 CI95::4.35-25.54, p value<0.01) were more likely 
follow up events in patients having an ID consultation.  The outcomes did not differ 








Table 12 Perprotocol Analysis                                                  
  
Control(40) 
No ( %) 
 
ID(70) 














21(52.50) 48(68.57) 1.97(0.89-4.39) 0.09 
Ethnicity 
   0.98‡ 
Chinese vs. Malay 
20(50.00) vs. 11(27.50) 38(54.29) vs. 18(25.71) 0.86(0.34-2.17) 0.75 
Chinese vs. Indian 
20(50.00) vs. 5(12.50) 38(54.29) vs. 8(11.43) 0.84(0.24-2.9) 0.78 
Surgical department  
2(5.00) 16(22.86) 0.18(0.04-0.82) 0.01 
Mode of acquisition 
   0.22‡ 
Community vs. Nosocomial 
6(15.00) vs. 10(25.00) 15(21.43) vs. 25(35.71) 1(0.30-3.31) 1.0 
Community vs. Healthcare associated 
6(15.00) vs. 24(60.00) 15(21.43) vs. 30(42.86) 0.5(0.16-1.48) 0.21 
Source of bacteremia 
   0.41‡ 
Unknown vs. Superficial skin  
12(30.00) vs. 6(15.00) 20(28.57) vs. 14(20.00) 1.4(0.42-4.6) 0.58 
Unknown vs. Deep tissue source 
12(30.00) vs. 4(10.00) 20(28.57) vs. 14(20.00) 2.1(0.56-7.8) 0.27 
 Unknown vs. Line source  

















IVDU 1(2.50) 9(12.86) 5.75(0.70-47.21) 0.07 
Diabetes 





*Denotes median and  IQR for continuous variables, † Denotes the odd ratio for every unit change , for example, in this analysis a person 10 year older , would     
have an odds of 1.0510 times that of the younger, ‡ 
  
Control(40) 
No ( %) 
ID(70) 





6(15) 6(8.57) 0.53(0.15-1.77) 0.29 
Haemodialysis 
19(47.50) 20(28.57) 0.44(0.20-0.99) 0.05 
Liver disease 
2(5.00) 3(4.29) 0.85(0.14-5.32) 1.00 
Renal disease 
21(52.50) 26(37.14) 0.53(0.24-1.18) 0.12 
Infective endocarditis 
3(7.50) 11(15.94) 2.34(0.61-8.95) 0.25 
Follow up blood c/s 
23(57.50) 41(59.42) 1.08(0.49-2.38) 0.84 
TTE 17(42.50) 52(74.29) 3.91(1.71-8.92) <0.01 
TEE 1(2.50) 4(5.71) 2.36(0.25-21.91) 0.65 
Bone imaging 6(15.00) 17(24.29) 1.82(0.65-5.07) 0.25 
Abdominal imaging 9(22.50) 19(27.14) 1.28(0.52-3.19) 0.59 
Other imaging 5(12.50) 17(24.29) 2.25(0.76-6.64) 0.14 
Surgical intervention 
1(2.50) 20(28.57) 15.60(2.01-121.37) 0.009(0.042) 
Appropriate empiric antibiotic 
20/37(54.1) 39/69(56.82) 1.07(0.47-2.45) 0.80 
Appropriate definitive antibiotic 
10/37(24.3) 49/67(73.77) 7.81(3.02-20.24) <0.01(<0.001) 
In hospital mortality 
4(10.26) 13(19.12) 2.07(0.62-6.85) 0.23 
Blood recurrence 
6(15.00) 4(5.71) 0.34(0.09-1.30) 0.10 
  
78 






No ( %) 
Odds ratio P value 










49(59.04) 50(69.44) 1.58(0.81-3.07) 0.18 
Ethnicity 
   0.97‡ 
Chinese vs. Malay 
48(57.83) vs. 19(22.89) 40(55.56) vs. 18(25.00) 1.2(0.41-3.48) 0.74 
Chinese vs. Indian 
48(57.83) vs. 8(9.64) 40(55.56) vs. 8(11.11) 0.9(0.288-2.8) 0.73 
Medical department 
17(20.48) 17(23.61) 0.83(0.39-1.78) 0.64 
 
Mode of acquisition    ‡ 
Community vs. Nosocomial 
22(26.51) vs. 28(33.73) 15(20.83) vs. 25(34.72) 1.3(0.56-3.06) 0.62 
Community vs. Healthcare associated 
22(26.51) vs. 33(39.76) 15(20.83) vs. 32(44.44) 1.42(0.62-3.21) 0.85 
Source of bacteremia    0.20‡ 
Unknown vs. Superficial skin source 
32(38.55) vs. 13(15.66) 20(27.78) vs. 15(20.83) 1.84(0.72-4.67) 0.196 
Unknown vs. Deep tissue source 
32(38.55) vs. 9(10.84) 20(27.78) vs. 15(20.83) 2.66(0.98-7.2) 0.054 
Unknown vs. Line source 













IVDU 12.00(14.46) 9.00(12.50) 0.85(0.33-2.14) 0.72 
Diabetes 




*Denotes median and IQR for continuous variables, † Denotes the odd ratio for every unit change, for example, in this analysis a person 10 year older , would     






No ( %) 
Odd ratio P value 
Haemodialysis 21.00(25.30) 21.00(29.17) 1.22(0.60-2.47) 0.59 
Malignancy 15.00(18.07) 7.00(9.72) 0.49(0.19-1.27) 0.14 
Liver disease 4.00(4.82) 3.00(4.17) 0.86(0.19-3.97) 0.85 
Renal disease 24.00(28.92) 27.00(37.50) 1.48(0.75-2.89) 0.26 
Infective endocarditis 15.00(18.07) 11.00(15.49) 0.83(0.35-1.95) 0.67 
Follow up blood culture 51(61.45) 42(59.15) 0.91(0.48-1.74) 0.77 
TEE 8(9.64) 4(5.56) 0.55(0.16-1.91) 0.38 
TTE 57(68.67) 53(73.61) 1.27(0.63-2.56) 0.50 
Bone imaging 19(22.89) 17(23.61) 1.04(0.49-2.20) 0.92 
Abdominal imaging 21(25.30) 20(27.78) 1.14(0.56-2.32) 0.73 
Other imaging 19(22.89) 17(23.61) 1.04(0.49-2.20) 0.92 
Surgical intervention 14(16.9) 21(29.2) 2.02(0.942-4.37) 0.068 
Appropriate empiric antibiotic 45/80(56.25) 40/71(56.34) 1.08(0.56-2.09) 0.99 
Appropriate definitive antibiotic 47/79(59.42) 50/69(72.46) 1.85(0.89-3.85) 0.098 
In hospital mortality 12(14.63) 14(20.00) 1.46(0.62-3.40) 0.38 
Blood recurrences 9(10.84) 4(5.56) 0.48(0.14-1.64) 0.24 
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Table 14 Pertreatment analysis 
  
No ID consult(42) 
No(%) 
ID consult( 113) 













23(54.76) 76(67.26) 1.70(0.82-3.50) 0.15 
Ethnicity 
   0.92‡ 
Chinese vs. Malay 
22(52.38) vs. 11(26.19) 66(58.41) vs. 26(23.01) 0.78(0.335-1.85) 0.58 
Chinese vs. Indian 
22(52.38) vs. 5(11.90) 66(58.41) vs. 11(9.73) 0.73(0.22-2.3)  0.601 
Surgical department 
3(7.14) 31(27.43) 0.20(0.06-0.71) 0.01 
Mode of acquisition 
   0.01‡ 
Community vs. Nosocomial 
6(14.29) vs. 10(23.81) 31(27.43) vs. 43(38.05) 0.83(0.27-0.79) 0.74 
Community vs. Healthcare associated 
6(14.29) vs. 26(61.90) 31(27.43) vs. 39(34.51) 0.29(0.10-0.793) 0.016 
Source of bacteremia 
   0.55‡ 
Unknown vs. Superficial skin source 
12(28.57) vs. 7(16.67) 40(35.40) vs. 21(18.58) 0.9(0.3-2.63) 0.84 
Unknown vs. Deep tissue source 
12(28.57) vs. 5(11.90) 40(35.40) vs. 19(16.81) 1.14(0.35-3.7) ‡ 0.83 
Unknown vs. Line source 

















IV drug abuse 
1(2.38) 20(17.70) 8.82(1.14-67.92) 0.02 
Diabetes  
21(50.00) 44(38.94) 0.64(0.31-1.30) 0.21 
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*Denotes median and  IQR for continuous variables, † Denotes the odd ratio for every unit change , for example, in this analysis a person 10 year older , would     
have an odds of 1.0510 times that of the younger, ‡ 
 
  
No ID consult(42) 
No(%) 
ID consult( 113) 





20(47.62) 22(19.47) 0.27(0.12-0.57) <0.01 
Malignancy 
7(16.67) 15(13.27) 0.77(0.29- 0.59 
Liver disease  
2(4.76) 5(4.42) 0.93(0.17-4.97) 1.00 
Renal disease  
22(52.38) 29(25.66) 0.31(0.15-0.66) <0.01 
Infective endocarditis 
3(7.14) 23(20.54) 3.36(0.95-11.85) 0.05 
Follow up blood c/s 
24(57.14) 69(61.61) 1.20(0.59-2.47) 0.61 
TTE 
18(42.86) 92(81.42) 5.84(2.70-12.66) <0.01 
TEE 
1(2.38) 11(9.73) 4.42(0.55-35.36) 0.18 
Bone imaging 
6(14.29) 30(26.55) 2.17(0.83-5.66) 0.11 
Abdominal imaging 
10(23.81) 31(27.43) 1.21(0.53-2.75) 0.65 
Other imaging 
5(11.90) 31(27.43) 2.80(1.01-7.77) 0.04 
Surgical Intervention 
2(4.76) 32(28.32) 7.90(1.80-34.64) <0.01 
Appropriate empiric 
antibiotic 
21/39(53.76) 64/112(57.14) 1.05(0.49-2.23) 0.721 
Appropriate definitive 
antibiotic 
10/39(25.64) 87/109(79.81) 10.54(4.35-25.54) <0.01 
In hospital mortality 
5/41(12.20) 21/111(18.92) 1.68(0.59- 0.33 
Blood recurrences 













RESULTS 3: MOLECULAR EPIDEMIOLOGY OF SAB IN 























A representative subset of 130 strains first  episode of SAB was subjected to Spa typing. 
The 130 strains were obtained from 128 patients, as two patients had a polymicrobial 
bacteremia with MRSA and MSSA.  Overall, 72 MRSA and 58 MSSA were subjected to 
Spa typing.  For each unique isolate, a Spa type was designated using an online database 
(www.ridom.net).  
All the strains were typable. Table 15 shows the spa types in MRSA and MSSA.  Overall, 
38 spa types were obtained for 58 MSSA isolates and 9 spa types for 72 MRSA isolates. 
Sixty four  of the MRSA isolates (89%) belonged to two spa types namely t032 and t037. 
One patient with polymicrobial infection had a different spa type for MRSA (t037) and 
MSSA (t189) while the other patient had the same spa type (t037).  






Type No Type No Type No Type No Type No 
t008 1 t338 1 t4666 1 t1684 1 t037 49 
t015 1 t346 2 t4667 1 t170 1 t032 15 
t034 1 t3802 1 t548 1 t189 7 t1214 2 
t037 2 t382 1 t622 1 t2119 1 t129 1 
t084 4 t4209 1 t645 1 t213 2 t1566 1 
t1182 1 t4662 1 t692 1 t2171 1 t202 1 
t127 5 t4663 1 t693 1 t258 1 t291 1 
t1509 1 t4664 1 t701 2 t304 1 t3555 1 
t159 1 t4665 1 t731 1 t3155 1 t548 1 
t164 4 t4666 1 t903 1     
 
Figure 16 shows the clustering analysis of MSSA and MRSA spa sequences respectively.  
As seen here, MSSA was more genetically diverse than MRSA.  Maximum number of 
members within one clonal complex for MSSA was 10 as opposed to 49 (t037) for 
MRSA. Among MRSA there was no clustering seen at the level of wards.  
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 Table 16 gives the antimicrobial profile of the various MRSA spa types isolated. All 
MRSA were resistant to Ciprofloxacin with the exception of t202 (n=1) and t548 (n=1). 
Of the resistant Ciprofloxacin strains, all t032 isolates were sensitive to cotrimoxazole 
and gentamicin, while all the t037 isolates were resistant to these antibiotics. 
 A univariate analysis was performed to compare the patient characteristics and outcome 
of MRSA patients with t032 spa type (n=15) with t037 (n=49). In this analysis, 
pneumonia and infective endocarditis were more common in patients with t032 spa type 
infection. However, patient outcomes did not vary significantly between the two groups. 
Mortality rate was 5 and 18 % for t032 and t037 MRSA bacteremia respectively (Table 
17). 
Table 16 Antimicrobial profile of MRSA spa types 
*: Denotes sensitivity †: Denotes resistance 
 
Spa Type Numbers Cotrimoxazole Ciprofloxacin Clindamycin Gentamicin 
t032 15    S * R† S S 
t3555 1 S R S S 
t1214 2 S R S S 
t1566 1 R R S S 
t037 49 R R R R 
t129 1 S R S R 
t291 1 R R R R 
t202 1 S S S S 





Figure 16: Clustering of MRSA and MSSA 
 
 
                                                                        
 
 NUMBER OF MEMBERS PER SPA TYPE 
    <2              <20                                                    
     <5 
     <10         >20                                                                                            
MSSA    MRSA 
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Table 17 Comparison of patient characteristics and outcomes of spa type t032 and t037 MRSA bacteremia 
Pt Characteristics T037(n=49) t032 (n=15) Odds ratio p value 
Age 63.5(51-69)* 68.5(54.5-75.5)* 0.98( 0.94-1.02)† 0.40 
Male sex 36(73.5) 8(53.33) 2.84(0.88-9.13) 0.14 
Chinese vs. Malay 34(69.4) vs. 11(22.5) 12(80)  vs. 3(20) 1.36(0.32-5.67) 1.36(0.32-5.67) 
Source of bacteremia    0.46‡ 
Unknown source vs. Superficial Skin 8(16.3) vs. 11(22.5) 1(6.6) vs. 5(33.3) 0.24(0.024-2.48) 0.23 
Unknown source vs. Deep tissue source 8(16.3)  vs. 10(0.4) 1(6.6) vs. 4(26) 0.27(0.025-2.96) 0.28 
Unknown source vs. Line infection 8(16.3)  vs. 18(36.8) 1(6.6)  vs. 3(20) 0.5(0.04-5.15) 0.56 
Mode of acquisition     0.60‡ 
Healthcare associated infection  16(32.6)             5(33.3)   
 Nosocomial infection 32(65.3) 9(60)   
Diabetes 25(51) 10(66.7) 0.6(0.18-1.90) 0.28 
Pneumonia 3(6.1) 5(33.3) 0.14(0.03-0.67) 0.014 
Renal Disease 15(30) 9(56.2) 0.55(1.73-1.75) 0.31 
Malignancy 12(24.5) 0(0) 5.27(0.63-43.9) 0.054 
Hemodialysis 10(20.4) 3(20) 1.08(0.25-4.54) 1 
Apache Score 13(9-18)* 13(11-17)* 0.98(0.89-1.08)† 0.76 
Charlson Score 5.5(3-7)* 4(3-6)* 0.95(0.76-1.18)† 0.67 





*Denotes median and  IQR for continuous variables, † Denotes the odd ratio for every unit change, for example , in this analysis a person 10 year younger , 
would have an odds of 0.9810 times that of the older patient, ‡ p value on a global comparison usinf chi square test
Pt Characteristics T037(n=49) t032 (n=15) Odds ratio p value 
Bony metastasis 6(13.3) 1(7.6) 1.95(0.21-17.7) 0.58 
Visceral metastasis 2(4.4) 1(7.6) 0.59(0.05-7.04) 0.64 
Persistent bacteremia 13(30.3) 5(45.5)32 0.58(0.16-2.19) 0.33 
In hospital mortality 18(39.3) 5(33.3) 1.03(0.32-3.33) 0.7 



























Staphylococcus aureus bacteremia (SAB) is a well-known and leading cause of 
community and hospital acquired bacteremia. In spite of the availability of effective 
antibiotics, the mortality rate due to SAB is still reported at 20-30%(3-7). In addition, 
SAB can be complicated by infective endocarditis, metastatic seeding especially to the 
bone and viscera and recurrence.  There have been several reports on the SAB 
epidemiology, most of which are from the Western world. (3, 7-10), What appears in the 
last decade or so is that many countries have witnessed an increase in the incidence of 
SAB(3, 5) and the main epidemiological focus has been the growing problem of MRSA 
among SAB .The burden of MRSA bacteremia in terms of cost and resources is high.  
There have also been treatment related issues emerging in MRSA bacteremias with many 
strains showing a higher MIC to vancomycin, the most common antibiotic used for its 
treatment. In spite of this dynamic epidemiology, there have been scant reports that aim 
at defining the epidemiology and outcomes of SAB in the Asian Context. Hence, we 
conducted this study with the main aim to define the problem at a tertiary care center in 
Singapore. Our study is one of the largest cohorts of SAB patients to be studied 
prospectively in the Asian context. The main outcome measures of interest were the 
crude mortality rate, metastatic seeding and the recurrence with a special emphasis on the 
predictors of these adverse events. In addition, we also examined the effect of an ID 
consultation on the outcomes of SAB patients in a randomized trial, the first study of its 
kind to our knowledge.  Previous studies aimed at evaluating the effect of ID consultation 
have been mainly observational or interventional, but in a non-randomized manner(131, 
132).  We also conducted molecular typing on a subset of our SAB isolates with the aim 
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to define clonality and to look at possible epidemiological associations among major 
clones of MRSA or MSSA. 
6.1 Epidemiology 
The overall SAB rate in our tertiary care center was 3.42/1000 discharges with the 
MRSA bacteremia rate of 1.44/1000 discharges. These rates were higher than the median 
SAB rate of 1.59/1000 admissions at principal referral metropolitan hospitals in Australia 
or 2.32/1000 discharges according to an US report(163). This high rate is possibly the 
result of the case mix at our center, a teaching hospital. Various countries including 
Singapore have reported a higher MRSA hospitalization rate among teaching as 
compared to non teaching hospitals. In Singapore, the MRSA rate /1000 discharges was 
3.2 at the current center (National University Hospital) as compared to Changi General 
Hospital(164)( 0.7, Table 18).  These different rates might also be the result of different 
methods of detection of cases. In Australia SAB rate varied from 0.6-3.24 with referral 
metropolitan hospitals having higher rate than large metropolitan or private hospitals(10).   
In 1989, rates of nosocomial SAB rate was 1.13 per 1000 discharges among large 
teaching hospitals as compared to 0.44 per 1000 discharges among large non teaching 
hospitals in the US(13).  
The epidemiology of SAB in our study was defined by a high percentage of MRSA 
(42%) and healthcare related infection (79-80%). The proportions of SAB cases 
attributable to MRSA at our center were comparable to countries such as the United 
Kingdom and USA and much higher than those reported in Scandinavian countries 
(Figure 17).  As the majority of MRSA bacteremias are healthcare related and more 




Table 18 Incidence of MRSA infections in acute care hospitals per 1000 discharges 
and deaths (Adapted from MOH occasional paper 2007/23) 
  2002 2003 2004 2005 2006 
Alexandra Hospital 1.8 1.7 1.8 1.2 1.6 
National University of Singapore 4.0 4.2 4.1 3.7 3.2 
Tan Tock Seng Hospital 3.5 4.0 4.1 3.8 3.6 
Changi General Hospital 0.7 0.5 0.7 0.5 0.7 
Kandang  Kerbau Hospital 0.3 0,1 0,2 0,3 0,3 














Figure 17: Worldwide proportions of Staphylococcus infections due to MRSA   
            
 

















practices and set up adequate monitoring systems. Some of the measures implemented to 
tackle healthcare MRSA in various countries including Singapore include 
 Active surveillance of high-risk patients such as ICU patients.  
 Isolation, cohorting and management of colonized individuals 
 Emphasis on hand hygiene 
 Training of healthcare personnel 
The impact of these measures is evident from the fact that countries such as Denmark, 
and Finland which have implemented an active “search and destroy (S&D)” policy have 
low rates of MRSA infections and bacteremias (167-170). It is possible that the S&D 
policy may also be effective in a healthcare setting where MRSA is endemic such as our 
tertiary care centre. In a simulation model proposed by Boostma and colleagues, a 
combined approach of screening high risk patients on admission plus screening of 
contacts when an index case is notified and a stepwise implementation could decrease a 
high endemicity to levels as low as <1% within 6-12 years(171).   
6.2 Mortality 
In our study, we noted an in-hospital mortality rate of 29% among SAB cases. Mylotte 
and colleagues reported a 30-day mortality of 23.2 % among 293 bacteremic episodes 
reported at a tertiary care center in USA from 1995-1999(52). In another large cohort of 
724 patients in the US, the attributable mortality of SAB was 28%(75). Close to 
Singapore, in Thailand, a high attributable mortality was reported (48%) among SAB 
patients(63). Thus the mortality reported in our study was similar to the hospital reports 
from the Western World (52, 55, 57-59, 75).  
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In our study, the predictors of in hospital mortality in a multiple logistic regression 
analysis were MRSA infection, elderly age, malignancies, history of wide spread skin 
disease, and a higher Apache score. A localized skin source such as carbuncles or 
phlebitis was associated with a lower mortality rate as compared to an unknown source.  
As a substantial proportion of patients with SAB have underlying comorbidities, various 
comorbidity scores have been used for   adjusting the risk. Scores commonly in use are 
the Charlson Comorbidity index(64), APACHE II score(91), McCabe score(92) and Pitt 
bacteremic score(172). These scoring systems differ from each other in the parameters 
used. APACHE II score takes organ failure with the vitals and other laboratory 
parameters to generate a score, a higher score being associated with a worse prognosis. 
The score was primarily designed for use in ICU patients, however, has also been used in 
context of SAB infections. Various studies have also shown APACHE II to be an 
independent predictor of mortality in SAB patients (52, 69, 71).  Some believe that the 
Delta APACHE score (the difference in APACHE score on the day of bacteremia and a 
day before the bacteremia) is more predictive of mortality than the APACHE II score 
alone taken on the day of bacteremia(173). The Charlson Comorbidity score is generated 
based on comorbidities and different weights are given to comorbidities such as 
Myocardial Infarction, Connective tissue disorder, malignancies, and chronic liver or 
renal disease. In an evaluation of 166 patients with SAB, a Charlson score of 3 or more 
was an independent predictor of attributable mortality (p value<0.001). Both, APACHE 
II and Charlson index are age-adjusted indices.  McCabe score a simple scoring system 
classifies illness as rapidly fatal, ultimately fatal and non-fatal disease and was initially 
devised for the use of predicting fatality in patients with gram negative bacteremia. This 
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classification is based on physician’s decision and hence subjective in nature. It has been 
mainly used for comparing the illness severity in different subgroup analysis(92). The 
Pitt bacteremic score takes into account few parameters such as temperature, events of 
hypotension, cardiac arrest and mechanical ventilation to generate a score. A score of 4 or 
more is more likely to be associated with critical illness(172). There are scant reports on 
the comparison of these scores in predicting mortality, especially in the context of SAB 
patients.    
 In our study, we used the Charlson and the APACHE II score on the date of withdrawal 
of blood culture to look for an association with mortality. Although Charlson and 
APACHE II score were significantly associated with mortality on a univariate analysis, 
only APACHE II score was significant on the multivariate analysis. Our findings are in 
line to those observed by Poses and colleagues who found in a comparative evaluation 
the overall APACHE score to be more predictive of in-hospital mortality in critically ill 
patients than the Charlson score(174). The better prediction of mortality is perhaps the 
result of the vitals and laboratory parameters taken into account in the APACHE score 
unlike the Charlson score and hence a better indicator of the severity of underlying 
sepsis. In addition, not all patients with serious comorbidities contribute to SAB 
mortalities. This is particularly true for patients with a removable focus of infection such 
as a hemodialysis catheter. As mentioned earlier, we found such patients to have a 
favorable outcome in terms of a decreased mortality rate. Previous studies have noted 
also noted the same(144). In spite of these findings, the APACHE score is not feasible to 
use routinely. Not all the laboratory information is available especially in patients not 
critically ill and those admitted in the general wards. Hence, Charlson might still be a 
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useful index for adjusting comorbidities especially in settings where the resources and 
laboratory information is limited.  Our study did not look at the possibility of a 
combination of APACHE and Charlson parameters to predict mortality. In the above 
mentioned evaluation by Poses et al (174), the APACHE subscore based on the chronic 
organ insufficiency alone was not as predictive of mortality  as the Charlson index . This 
is not surprising given the range of comorbidities covered by the Charlson index, which 
could hence supplement the information available by APACHE score. We are yet to 
evaluate the effect and comparative evaluation of other scores such as Pitt bacteremia 
score.   
Some of the other factors predictive of SAB mortality in previous studies include elderly 
age(3-5, 7, 52, 54, 62, 64-66) ,  MRSA infection (67), a lung origin(4, 5, 7, 52, 62) , 
unknown source , septic shock(64, 65), endocarditis (4, 7), persistent bacteremia(62) and 
metastatic infection(62) ,  a greater severity of illness and comorbidities (4, 7, 62, 68-70) , 
a delay in institution of antibiotic (65) and nosocomial infection(54).  
There are several reasons for the marked variation in the predictors noticed among 
various studies. Firstly, a high proportion of SAB patients have serious underlying 
comorbidities that may be independently responsible for causing mortalities. Secondly, 
studies vary in the definitions of mortality used. Different studies use attributable 
mortality, 30-day or in-hospital mortality. Although attributable mortality would be ideal, 
it is sometimes subjective. Thirdly, local epidemiology of SAB such as the mode of 
acquisition, MRSA percentage and population characteristics in particular the age profile 
and prevalence of comorbidities such as diabetes vary. Fourthly, most studies reflect the 
situation in individual tertiary care centers and the cohort studied are small numbers.  
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In spite of the heterogeneity, some mortality risk factors appear to be more commonly 
reported across studies such as age or MRSA infections. The impact of MRSA was also 
extensively studied in a meta-analysis including 31 studies concluding that MRSA was 
indeed associated with a higher mortality(67). The role of modifiable factors such as 
antibiotic treatment and source of infection is still unclear. In our study, we found that a 
skin source was associated with a lower mortality rate, presumably because it is more 
amenable to eradication. This finding is in line with the results of Kim et al (144).  
We could not demonstrate a difference in mortality rates among patients receiving 
appropriate versus inappropriate antibiotics. In our study, around 60% of patients who 
died or survived were likely to receive appropriate definitive antibiotics (p value =0.87). 
Previous studies aimed at looking at the effect of appropriate antibiotic on mortality 
outcome have been conflicting. While some   studies show that   optimal antibiotic is 
associated with lower mortality (9, 73, 141, 142), other studies fail to find such a 
difference (31, 62, 89). 
 Previous studies have also shown that vancomycin is associated with higher mortality or 
recurrence among MSSA bacteremia(84, 134, 135, 140). In our SAB series, only 8 
MSSA patients received vancomycin of which two had serious penicillin allergies. We 
also found that patients with MRSA bacteremia were more likely to receive appropriate 
antibiotics than MSSA patients, presumably because of our criteria of the antibiotic type 
(including cloxacillin and cefazolin while considering meropenem or augmentin as 
inappropriate) and high dosage of betalactams to define adequacy of antibiotics for 
MSSA bacteremia. Many patients with suboptimal antibiotics were receiving cloxacillin 
at a dose of 1-2gm /day. A previous study conducted by Jensen and colleagues stress the 
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importance of correct dosing of beta-lactams such as cloxacillin(65). They found a higher 
mortality rate among patients receiving less than 4 gm of cloxacillin /day. Although the 
cut–off set up by the Jensen study was 4gm/day, many clinicians still prefer 
administering a higher dose of cloxacillin (~8gm/day) so as to prevent recurrences and 
metastatic seeding of bacteria. This is mainly driven by the serious nature of the 
condition itself. More studies are required to determine the actual suboptimal dose at 
which poor outcomes such as recurrence, metastatic infection or mortality becomes more 
common.  Without evidence, we believe it would be wise to stick on to advocating   a 
high dose of cloxacillin in MSSA bacteremic patients.  
We also noted in our study that a history of widespread skin disease was an independent 
predictor of mortality.  There are scanty reports on this association, perhaps the strongest 
being the study conducted by Fowler and colleagues(75). They included 724 patients of 
SAB, 43% of whom had complicated bacteremias defined by attributable mortality, 
metastatic infection or recurrence. Skin findings suggestive of an acute systemic illness 
was a significant risk factor for complicated bacteremia in this cohort (OR: 2.04, 
p=0.002). However, it was not clear in this study whether the skin findings were 
suggestive of mortality as well or was related to other complications such as recurrence 
or metastatic infection. As many patients in our population had previous history of skin 
disease, in particular eczema, it is possible that underlying autoimmunity and use of 
immunosuppressives could have predisposed these patients to SAB septicemia. However, 
the mortality rate was not different in those who received steroid/immunosuppressive 
therapy versus others. It is also possible that many patients had Traditional Chinese 
Medicine (TCM), which is very popular in this region and thought to have 
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immunosuppressive effects.  The role of TSST 1 toxin cannot be ruled out. In our study, 
we did not seek to detect the presence of this toxin. Pathophysiologically, Staphylococcus 
aureus can secrete a toxin called TSST 1 which is associated with skin lesions and shock 
and indeed shock  has been noticed as an independent predictor of mortality.  
6.3 Metastatic infection and Recurrence 
As mentioned earlier, Staphylococus aureus bacteremia is frequently complicated by 
metastatic seeding to the endocardium, viscera and bones and other sites. The overall 
prevalence of complicated bacteremia varies from 11 to 53%(175, 176) and the 
prevalence of endocarditis ranges from 5-15%(4, 5, 7, 60, 65). The consequences of such 
dissemination are a prolonged course of antibiotics, higher mortality rate and chances of 
recurrence in the future. Hence, it is important to define the predictors of metastatic 
dissemination so that high-risk patients undergo extensive evaluation.  
In our study, we reported the metastatic seeding of only those patients with an LOS of 
more than 4 days as the others could not undergo relevant investigations to ascertain the 
same. The prevalence of metastatic seeding and infective endocarditis was 25% and 
14.5% respectively and hence in line with those reported elsewhere (see above).  
Predictors of metastatic dissemination were intravenous drug abuse and persistent 
bacteremia. We defined persistent bacteremia as a positive blood culture taken 72 hours 
after the initiation of an effective antibiotic class. Various studies conducted previously 
have used different definitions to define persistent bacteremia (53, 75). In spite of 
variations, most studies report an association between persistent bacteremia and 
metastatic dissemination(53)/infective endocarditis(76))/complicated bacteremia(75). In a 
prospective observational study of 245 SAB cases, Khatib and colleagues not only found 
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this association, but also were able to correlate the bacteremia duration to the 
complication rate(53). Based on this and another large cohort, a complicated outcome can 
be expected to be anywhere between 30-50% in patients with a persistent bacteremia of 3 
days or more. In light of this information, many investigators have suggested a routine 
follow up blood culture be withdrawn 2-4 days after the onset of bacteremia. In our 
study, 68%( 143/253) of patients with LOS>=4 days had a repeat blood culture within 4 
days of bacteremia and an additional 16% of bacteremias within 7 days. Hence, although 
majority of patients had a repeat blood culture within 7 days, we feel there may a need to 
increase the coverage so that a repeat culture is available within 4 days of bacteremia  
As an echocardiographic modality for diagnosing vegetations in IE, TTE and TEE are 
widely used. Although, TTE is a simpler non-invasive and cost effective method, it is less 
sensitive than TEE in the detection of vegetations. Previous studies have shown that TEE 
picks up more vegetations equally with a negative or indeterminate TTE result(77).  With 
this and many other studies showing the advantage of TEE (177), many investigators 
have suggested that all patients with SAB be routinely evaluated with TEE, the major 
deterrent to this  being the cost and invasive nature of the procedure. Recent studies have 
also shown that a TEE might not be as costly as perceived and indeed a TEE guided 
therapy could save more than $142 million healthcare expenditures while providing 
similar outcomes in SAB patients(178). On the other hand, the overuse of TTE has also 
been challenged especially in a clinical scenario where the pretest probability of the 
disease, in this case infective endocarditis is low (179). The primary aim of our study was 
not to compare the two modalities, however, we tried to determine if patients were 
adequately receiving TTE/TEE. Some findings require special attention. Firstly, in our 
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study, 180 of 300 patients had an echocardiographic evaluation for vegetations of which 
only 14 patients ( 14/300=4.6%)  had a TEE an any point after the detection of  SAB.  In 
another study, around  20% of patients had a TEE(132). Hence, is it possible that we 
might be advocating TEE less often than required.  Secondly, TTE was more commonly 
advocated when a patient had an ID consultation also suggesting a need to increase the 
use of a routine TTE following SAB.  
Thirdly, among 33 clinical endocarditis patients, 29 showed vegetations with TTE. In two 
TTE negative patients, vegetations were detected with TEE. Although, on first 
impression, TTE appears to have performed well, it is tough to conclude the same in the 
absence of TEE being done in many patients. It is possible that more cases of 
endocarditis occur and  these could be missed by TTE and picked up by TEE. Currently, 
at our centre a a sequential strategy appears to be in place, TEE mainly being reserved for 
those with a high index of suspicion and negative TTE. Whether such a strategy is 
adequate to identify all the endocarditis cases is not certain. In a simulation model, 
Heidenreich and colleagues(180) have shown that such  a sequential strategy might be 
less cost effective and offer the same quality –adjusted life expectancy as compared to 
TEE as the initial diagnostic modality. In the same study, the investigators showed that 
the greatest benefit of an initial TEE was when the pretest probability of the disease was 
between 4-40% and precluded the additional utility of echocardiography in patients with 
a probability of less than 4% or more than 40%.  In practice, it might not be easy to 
decide which patient would fall in the bracket of 4-40% especially in the absence of well-
defined clinical parameters. Although the authors above provided a extensive pretest 
probability list for different clinical scenarios, this is based on limited previous reports 
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and not indeed convenient in an actual clinical scenario. Thus, more studies comparing 
the two modalities are required in the local context and in particular reference to SAB to 
determine the exact strategy for their use.  
In our study, only 27% of the metastatic infections were from MRSA bacteremia and 
20% of infective endocarditis was attributable to MRSA. Our proportion of metastatic 
infections and IE caused by MRSA, although slightly lower than that observed in the US 
(33-40%)(60, 74) , seem to reiterate the fact that metastatic dissemination can no longer 
be considered a sole entity of MSSA bacteremia among IVDU.  Also, among MRSA 
patients, isolated bony infection appears to be as common as endocarditis (7 vs. 8 out of 
126 MRSA cases respectively). In our study, we noticed an association between bony 
metastatic infections and a higher vancomycin MIC among MRSA. As previous studies 
have also shown an association with hVISA phenotype and development of 
osteomyelitis(124) and a higher mortality  among patients with a higher vancomycin 
MIC(181), we believe that symptoms such a joint or back pain in patient with MRSA 
bacteremia especially when associated with  persistent bacteremia and  a higher 
vancomycin MIC should undergo  further  diagnostic imaging and managed aggressively. 
The rate of recurrence was 9.9% and comparable to other studies (9, 53-55, 83, 84). Due 
to the small numbers, we did not look for associations for recurrence. The time to 
recurrence ranged from 16-260 days. While some investigators believe that believe that 
relapses occur earlier than reinfection. (70, 86), we could not ascertain the same, as we 
are yet to perform the genotyping of the recurrent strain.   
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6.4 Infectious Disease Consultation 
There are very few studies that address the issue of the impact of an ID consultation on 
the outcomes of patients with SAB. In the later half of 2007, we started recruiting 
patients in a randomized trial to look at the effect of an ID consultation. This design had 
several strengths. Essentially, we were comparing two arms (ID consult vs. Control), 
similar characteristics for who were achieved by randomization. We did not deny patients 
in the control arm an ID consultation which was left to the discretion of the primary 
physician. This design enabled us to perform three different forms of analysis to look for 
any differences in outcomes. To our knowledge, this is the first randomized controlled 
trial to look for the impact of an ID consultation in SAB. Although there is evidence from 
a previous study that patients with an ID consultation have improved outcomes, study 
design was flawed by the fact that patients characteristics in the group with or without ID 
consultation were not comparable(131).  
 Outcomes of 72 patients in the ID arm and 83 patients in the control arm were compared 
with an intention to treat, per protocol and pretreatment analysis. Notably, patients in the 
ID arm were more likely to have better process measures of receiving more appropriate 
antibiotics and surgical intervention in a per-protocol analysis. However, there was no 
difference in overall outcomes noted in spite of a better standard of care in patients with 
Staphylococcus aureus bacteremia. We believe that this is due to the small sample size or 
because we included the all-cause mortality instead of the attributable mortality. Our 
future aim would be to have an independent review of the cases for the attributable 
mortality and reanalyze our results. It is also possible that other factors driving mortality 
are stronger and may not be modifiable by management of SAB or an ID consultation. 
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Whilst mortality is one of our parameters and the strongest outcomes to advocate a 
mandatory ID consultation, we have yet to evaluate the effect of the ID consultation on 
other outcome parameters such as length of stay or hospital costs.  By far the strongest 
outcome modified by an ID consultation was shown by Fowler and colleagues wherein 
patients for whom the physician’s followed the ID recommendations were less likely to 
have a recurrence(131). However, in this study, patients who did not follow the 
recommendations were more likely to be hemodialysed, which could have thus been a 
confounder. In our study we found fewer recurrences in patients with an ID consultation, 
however,  this was not statistically significant. Some of the reasons might be due to the 
small numbers or a short duration of follow up, which in some cases was only 8 weeks.   
Thus, it is premature to conclude based on our limited data that a mandatory ID 
consultation would not improve outcomes.  
6.5 Problem of high Vancomycin MIC and recognition 
 The lack of sensitivity of standard microbiological methods in detecting higher 
vancomycin MIC and thus predicting VISA/hVISA is well known.  In a study conducted 
in Israel, additional testing revealed that almost 75% of the hVISA isolates would have 
been missed without specific testing(123).  Thus, there is a need of a simple diagnostic 
screening assay to routinely test MRSA isolates for hVISA/VISA. Population profile 
analysis (PAP) is considered the gold standard for diagnosis of hVISA, however, is 
cumbersome to perform(127). As per a CDC testing algorithm, all MRSA isolates should 
be screened for hVISA on a Vancomycin screen plate (BHI agar with 6ug/ml of 
vancomycin). However, such a high level of vancomycin might miss cases of VISA. A 
recent multicentric evaluation revealed that this method had a sensitivity of only 
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44%(182).  In this study, MHA with 5ug/ml of vancomycin or teicoplanin and E-Test 
macromethod (ETM) were also evaluated. The best performance was obtained with ETM 
with a sensitivity and specificity of 99% and 93.3%. The ETM method differs from the 
routine E-Test MIC determination by employing a higher inoculum of the bacteria. This 
method is less cumbersome than PAP and thus becoming increasingly popular in 
Microbiology laboratories.  The exact determination of the MIC is vital to guide the 
antimicrobial therapy especially in patients with persistent bacteremia occurring in spite 
of adequate vancomycin therapy. Currently, there is no consensus on whom should be 
screened for hVISA/VISA and thus the decision of a routine testing versus a clinical 
based depends on the individual centers.  
In the absence of additional laboratory testing, we could not determine how many of our 
strains were hVISA. Based on standard detection method of VITEK, 21% of the MRSA 
isolates in our cohort had an MIC of 2 or above with only one frank VISA. There was no 
clonality observed among strains showing a higher MIC value. Such a high prevalence of 
MRSA with a vancomycin MIC >= 2 have also been noted by other investigators(120, 
183, 184). In our study, MRSA strains with a higher MIC were associated with more 
persistent bacteremia, recurrence and bony metastatic infections. Although the mortality 
rate was higher in patients with a higher MIC, this was not statistically significant. This 
poor outcome among patients with higher MIC is in line with those observed by other 
investigators(118, 119).  
6.6 Genotyping 
We used spa typing to define the bacteremia isolates in our study. Previous studies have 
shown Spa Typing to be a useful genotyping tool. It is an easy typing method involving 
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the sequencing of a single genetic locus and results obtained can be compared with those 
obtained in other laboratories. Various studies have shown that this typing has a 
discriminatory index in between that of PFGE and MLST and hence, is a useful tool for 
tracking evolutionary trends or investigating an outbreak (147, 151, 153, 154).  In our 
study, we used this typing method to define the clonality of our isolates and to establish 
associations with the epidemiological and microbiological characteristics.  
Majority of the MRSA (89%) isolates belonged to two major clones, namely Spa type 
t032 and spa type t037. t032 has been mapped to the E-MRSA clone/ST22-SCCmecIV 
and t037 has been mapped to the ST-239-241 SCCmec III (Table 2). Both these clones 
are well known healthcare clones and differ mainly in their antimicrobial profile, t032 
being sensitive to cotrimoxazole and gentamicin and t037 being resistant to both these 
antibiotics. Previous genotyping studies from Singapore have also shown the presence of 
these two circulating clones (156, 157).  Hsu and colleagues at the Singapore General 
Hospital established a theory of progressive displacement of ST 239 by ST 22. They 
found a dramatic rise in the frequency of ST22 from 22% of all MRSA isolates (both 
bacteremic and non bacteremic) in 2003 to 33% in 2005(156).  In our study, E-MRSA 15 
constituted 21% of all blood isolates, thus the rate seems to be stable since 2005.  There 
have been concerns about a worse outcome with E-MRSA 15. However, on our study, 
the outcomes of spa type t032 (E-MRSA) were similar to t037 in terms of mortality rates 
and recurrences. A previous study conducted at a different tertiary care center in 
Singapore have also noted the same results(73)  
 A cluster analysis of all spa types of MRSA showed a close association with the 
antimicrobial profile of these isolates. The spa types closely related to t032 (t3555 and 
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t1214) were sensitive to cotrimoxazole and gentamicin. T129 and t291 were closer to 
t037 than t032 and had a more resistant phenotype mirroring the profile of t037. And the 
two-ciprofloxacin sensitive strains of MRSA were distant to both these healthcare clones.  
C-MRSA appeared to be rare in our study with only documented case as defined by the 
clinical picture, antimicrobial profile (ciprofloxacin sensitive) and the spa type (t202).  
This finding is line with a previous report(20).  C-MRSA has been previously 
documented in Singapore in mainly skin and soft tissue infection. Genotypically, 
majority are ST 30 and PVL positive(21).  Currently, many other countries have 
witnessed a rise in community onset bacteremia. In a recent PFGE analysis of 864 
invasive MRSA isolates, 82% of which were from blood, USA 300, the predominant C-
MRSA clone in the USA was isolated from 66% of community cases and 22% of 
healthcare infections. Moreover USA 100 a predominant healthcare clone was seen in   
23 % of community onset bacteremias(8). Thus, the distinction appears to be becoming 
blurred between healthcare and community clones and similar phenomenon has also been 
observed in Australia(18). There have been concerns of a poor outcome of C-MRSA 
infections as a result of carriage of the PVL toxin. However, several studies show that the 
outcomes and risk factors of USA 300 bacteremias appear to be similar to non USA 300 
bacteremias or community MSSA infections (18, 155, 185).  The problem of C-MRSA 
bacteremia is also recognized in certain Asian countries such as Taiwan where according 
to one report, 33 % of all community onset Staphylococcus aureus bacteremias were 
MRSA in nature(19). Majority of the strains encountered there were ST 59 and the PVL 
carriage was not uniform(185). Thus, with countries like Australia, USA and Taiwan 
witnessing a rise of community acquired MRSA infections, a constant vigil is warranted, 
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especially when an abnormal antibiogram or the common community phenotypes ST 
30(spa types t138, t021, t019, t018, t012, t276, t318, t338, t391), ST 59(spa types t444, 
t216, t199)  or ST 8 ( spa type t008) are encountered.  
Overall, we found Spa Typing to be an easy and cheap screening tool for typing 
Staphylococcus aureus strains. The data available can be compared with those in other 
countries, certain spa types can be mapped to MLST types and useful clustering and 
epidemiological associations can be drawn.   
6.7 Limitations 
1. Our study was conducted at a single tertiary care centre in Singapore, hence it is 
possible that the results here reflect the local situation and not what is prevalent in the 
entire country. Although we were able to observe the outcomes of 300 patients, much 
larger than what has been the case with other studies, we believe it is still not large 
enough particularly to look for associations for less common events such as VISA, 
persistent bacteremia and recurrence. Also, we did not evaluate the length of stay and the 
hospitalization costs of bacteremia.  
2. The trial analysis, although randomized, was still not ideal as almost 50% of patients in 
the control arm received an ID consult. However, it was not ethical to deny patients in 
need of a consult in the control arm; hence the only way to look for differences in 
outcome would be a larger recruitment. We did not analyze the attributable mortality 
differences in both the trial arms.  
3. We were not able to perform MLST or PFGE on our strains of SAB.  However, we 
believe that this do not confound our findings as Spa typing, the genotyping method used 
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has been extensively validated previously by various investigators and the common spa 
types isolated in our study are well known clones with MLST mapping.  
4. Most of the patients with a LOS shorter than 4 days could not be evaluated for 
metastatic infection due to the lack of imaging.   
6.8 Conclusions 
SAB appears to be a well-defined entity with a hospitalization rate, mortality and 
complications similar to reports from Western countries. The high proportions of 
infections caused by MRSA warrants an intensification of our current infection control 
practices. The high rate of comorbidities in patients with SAB has lead to the use of 
comorbidity scores for adjustments in analysis. While APACHE score appears to be more 
predictive of mortality, it is more cumbersome and may not be feasible in all situations.  
In such circumstances a Charlson score could be used and may also be used in 
conjunction to APACHE score to supplement the information.  There is a need to monitor 
the development of complications more closely with the use of follow up blood cultures 
as a surrogate marker of persistent bacteremia and increased use of TEE is desirable. A 
high percentage of our MRSA strains had an MIC of 2 or above and was associated with 
a poor outcome. The genotyping using Spa typing revealed two major clones of MRSA 
(E-MRSA 15 / ST239-241). Amidst concerns of the poor outcome with the recent 
emergence of E-MRSA15, we found that the outcomes of such patients were similar to 
ST239-241. Spa typing was an effective and simple tool to define these clones. We are 
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1M Tris-Cl pH 8.0 solution 
0.5 M Sodium EDTA solution 
Triton® X-100 
Sterile water 
Lysozyme (10mg/ml) solution 
Lysostaphin ( 1mg/ml) solution 
QIAGEN DNeasy® Blood and tissue Kit 
1.5-2 ml microcentrifuge tube 
Heating block( at 56OC) 
Water bath ( at 37O C) 
Centrifuge 
 
Preparation of enzymatic lysis buffer 
 
Enzymatic lysis buffer (stock) was prepared in the proportion given below (Table 1). The 
final working solution was prepared fresh by adding lysozyme and lysostaphin toi the 
stock in  the proportions given in Table 2 
 
Table 1:  Constitution of the enzymatic lysis buffer stock  
 
Constituents For 10 ml lysis solution 
( in µl) 
For 50 ml lysis solution 
( in µl) 
Tris Cl ( 1M) pH 8.0 200 1000 









Amount of lysis    
buffer 
Lysostaphin ( 1mg/ml) 
( in µl) 
Lysozyme ( 10mg/ml) 
( in µl) 
5 1000 30 30 
10 2000 60 60 
15 3000 90 90 
20 4000 120 120 
25 5000 150 150 








1. 8-10 colonies of  Staphylococcus aureus  from a blood agar plate ( subcultured the 
previous day)  was suspended in 180ul of lysis buffer in a microcentrifuge tube 
2. The mixture was vortexed 
3. Incubate for 30 min at 37OC 
4. Add 25µl of Proteinase K and 200µl of Buffer AL ( without ethanol). Mix by 
vortexing 
5. Incubate at 56oC for 30 minutes 
6. Add 200µl of ethanol to the samples and mix thoroughly by vortexing 
7. Place the mixture into a DNeasy Minispin column placed in a 2ml collection tube 
(provided in the kit). Centrifuge at 8000rpm for 1min. Discard the flow-though 
and collection tube 
8. Place the DNeasy Minispin column in a new collection tube. Add 500µl of Buffer 
AW1 and centrifuge at 8000rpm for 1min. Discard the flow-though and collection 
tube 
9. Place the DNeasy Minispin column in a new collection tube. Add 500µl of Buffer 
AW2 and centrifuge at 14000rpm for 3min. Discard the flow-though and 
collection tube 
10. Place the DNeasy Minispin column in a clean 1.5-2 ml microcentrifuge tube and 
pipet 200µl of Buffer AE( elution buffer) directly on the DNeasy membrane. 
Incubate at room temperature for 1 min and then centrifuge at 8000rpm for 1 min 
11. Discard the flow through and store the DNA in microcentrifuge tube at -20oC 

























Appendix 2:  PCR Purification  
The protocol used was based on the number of bands visualised on a gel. If a single band 
was present for each sample then the QIAquick PCR Purification Kit  was used( Protocol 
1). If more than one bands was present , then the sample was rerun with 20ul of PCR 
products and each individual band was cut and DNA extracted using the QIAquick gel 
extraction kit ( Protocol 2).  
 
PROTOCOL 1 ( PCR PURIFICATION) 
1. Add 5 volumes of buffer PBI to 1 volume of the PCR sample into the 1.5 ml 
microcentrifuge tube and mix. 
2. Place a QIAquick spin column in a provided 2 ml collection tube 
3. Transfer the sample mixture from the 1.5 ml microcentrifuge tube to the 
QIAquick spin column with the collection tube. 
4. To bind DNA, centrifuge the QIAquick column for 30 – 60 s. 
5. Discard the flow-through in the collection tube. Replace the collection tube to the 
same spin column. 
6. To wash, add 0.75 ml Buffer PE to the QIAquick column and leave it to stand for 
5 min. 
7. Centrifuge the QIAquick column for 30 – 60 s. 
8. Discard the flow-through in the collection tube and reuse it. Centrifuge the 
column for an additional 1 min. 
9. Discard the collection tube and place the QIAquick column in a new, labelled 1.5 
ml microcentrifuge tube. 
10. To elute the DNA, add 50 µl Buffer EB to the center of the QIAquick membrane 
and leave it to stand for 1 min. Then centrifuge the column for 1 min. 
11. Discard the QIAquick column and keep the purified DNA collected in the 1.5 ml 
microcentrifuge tube. 
PROTOCOL 2 ( GEL EXTRACTION ) 
 
1. Excise the DNA fragment from the agarsoe gel using a clean scalpel 
2. Weigh the gel slice in a colorless tube. Add 3 volumes of Buffer QG to 1 volume 
of gel ( 100mg~100 µl) 
3. Incubate at 50oC for 10 min. Vortex intermittently every 2-3 min 
4. After the gel slice has dissolved completely, check that the mixture is yeloow in 
color.  
5. Add 1 gel volume of isopropanol to the sample ans mix 
6. Place a QIAquick spin column in a 2 ml collection tube ( provided in the kit) 
7. To bind DNA, add the sample to the QIAquick column and centrifuge for 1min 
8. Discard the flow through  and place the QIAquick column in the same collection 
tube.  
9. Add 0.5 ml of Buffer QG to QIAquick and centrifuge for 1min.  
10. To wash, add 0.75 ml Buffer PE to the QIAquick column and leave it to stand for 
5 min. 
11. Centrifuge the QIAquick column for 30 – 60 s. 
12. Discard the flow-through in the collection tube and reuse it. Centrifuge the 
column for an additional 1 min. 
  
13. Discard the collection tube and place the QIAquick column in a new, labelled 1.5 
ml microcentrifuge tube. 
14. To elute the DNA, add 50 µl Buffer EB to the center of the QIAquick membrane 
and leave it to stand for 1 min. Then centrifuge the column for 1 min. 
15. Discard the QIAquick column and keep the purified DNA collected in the 1.5 ml 
microcentrifuge tube. 
 
 
 
 
 
 
 
 
 
 
